TradeLegend的个人主页 - 老虎社区

TradeLegend

TradeLegend

暂无个人介绍

IP属地：未知

7关注

10粉丝

0主题

0勋章

2021-08-14

🤑

Tesla seeks to reduce board members’ terms, make other changes in October shareholder meeting

2021-07-30

👍

抱歉，原内容已删除

2021-12-13

🤑

抱歉，原内容已删除

2021-10-05

👍

抱歉，原内容已删除

2021-08-05

🤑

抱歉，原内容已删除

2021-12-20

🤑

Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade

2021-12-16

🤑

All the doves at the Fed have become hawks

2021-11-02

👍

抱歉，原内容已删除

2021-09-15

🤑

U.S. stocks close lower on worries over recovery, corporate tax hikes

2021-08-25

🤑

抱歉，原内容已删除

2021-08-16

🤑

抱歉，原内容已删除

2021-10-15

🤑

S&P 500 surges, biggest daily percentage rise since March on earnings, data

2021-10-09

👍

抱歉，原内容已删除

2021-10-01

🤑

抱歉，原内容已删除

2021-09-04

🤑

抱歉，原内容已删除

2021-07-30

👍

抱歉，原内容已删除

2021-12-18

🤑

DaVita authorizes additional $2B share repurchase

2021-11-20

🤑

Bristol Myers Stock Keeps Skidding on FDA Heart Drug Review

2021-09-03

🤑

抱歉，原内容已删除

2021-08-31

🤑

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3565930395680990","uuid":"3565930395680990","gmtCreate":1602836610802,"gmtModify":1706620606114,"name":"TradeLegend","pinyin":"tradelegend","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":10,"headSize":7,"tweetSize":134,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"60.12%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.57%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":693599866,"gmtCreate":1640047130884,"gmtModify":1640047131033,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/693599866","repostId":"1184187118","repostType":4,"isVote":1,"tweetType":1,"viewCount":2176,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693069194,"gmtCreate":1639930012033,"gmtModify":1639930012195,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/693069194","repostId":"1122414343","repostType":4,"repost":{"id":"1122414343","kind":"news","pubTimestamp":1639884070,"share":"https://www.laohu8.com/m/news/1122414343?lang=&edition=full","pubTime":"2021-12-19 11:21","market":"us","language":"en","title":"Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade","url":"https://stock-news.laohu8.com/highlight/detail?id=1122414343","media":"Seeking Alpha","summary":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5","content":"<p>The healthcare stocks in the S&amp;P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&amp;A prospects. <a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.</p>\n<p>Among stocks with more than $2B market capitalization and 100K average daily volume over the past week, <a href=\"https://laohu8.com/S/ARNA\">Arena Pharmaceuticals </a> dominated with a ~83.8% rise after <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. <a href=\"https://laohu8.com/S/CERN\">Cerner </a> also joined the M&amp;A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from <a href=\"https://laohu8.com/S/ORCL\">Oracle </a> for the electronic-medical-records company.</p>\n<p>Vaccine developer, <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.</p>\n<p><a href=\"https://laohu8.com/S/BHVN\">Biohaven Pharmaceutical </a> posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, <a href=\"https://laohu8.com/S/ROIV\">Roivant Sciences </a> added ~22.6%.</p>\n<p>Notable gainer: <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the <a href=\"https://laohu8.com/S/NWY\">New York</a>-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.</p>\n<p>Among worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.</p>\n<p>Last week’s best performer, <a href=\"https://laohu8.com/S/BHG\">Bright Health Group</a>, crashed ~13.1%, hurt by the sole Sell rating issued by <a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a> even as the investment bank kicked off its coverage on managed care with largely positive views.</p>\n<p>Allogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic <a href=\"https://laohu8.com/S/00699\">CAR</a> T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax, Vir among healthcare gainers, Pfizer posts best rally in a decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-19 11:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the ...</p>\n\n<a href=\"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4534":"瑞士信贷持仓","ORCL":"甲骨文","BK4533":"AQR资本管理(全球第二大对冲基金)","ARNA":"阿里那","CERN":"美国塞纳","BK4007":"制药","PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122414343","content_text":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.\nAmong stocks with more than $2B market capitalization and 100K average daily volume over the past week, Arena Pharmaceuticals  dominated with a ~83.8% rise after Pfizer  agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. Cerner  also joined the M&A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from Oracle  for the electronic-medical-records company.\nVaccine developer, Novavax  jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.\nBiohaven Pharmaceutical  posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, Roivant Sciences  added ~22.6%.\nNotable gainer: Pfizer (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the New York-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.\nAmong worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.\nLast week’s best performer, Bright Health Group, crashed ~13.1%, hurt by the sole Sell rating issued by Goldman Sachs even as the investment bank kicked off its coverage on managed care with largely positive views.\nAllogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic CAR T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.","news_type":1,"symbols_score_info":{"ARNA":0.9,"CERN":0.9,"ORCL":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1820,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699270807,"gmtCreate":1639824405751,"gmtModify":1639824405859,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/699270807","repostId":"1189235922","repostType":4,"repost":{"id":"1189235922","kind":"news","pubTimestamp":1639809269,"share":"https://www.laohu8.com/m/news/1189235922?lang=&edition=full","pubTime":"2021-12-18 14:34","market":"us","language":"en","title":"DaVita authorizes additional $2B share repurchase","url":"https://stock-news.laohu8.com/highlight/detail?id=1189235922","media":"Seeking Alpha","summary":"DaVita  Board of Directors increased the authorization under the existing share repurchase program b","content":"<p><a href=\"https://laohu8.com/S/DVA\">DaVita </a> Board of Directors increased the authorization under the existing share repurchase program by $2B in additional repurchasing authority.</p>\n<p>The amount of shares authorized to be repurchased under the new authorization does not include the amount remaining under the company’s existing share repurchase program authorized on December 10, 2020 .</p>\n<p>Some bearish commentary and rating on the stock by SA contributor who writes: 'The company appears to be overvalued, and there are several challenges facing the company in the future.'</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DaVita authorizes additional $2B share repurchase</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDaVita authorizes additional $2B share repurchase\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-18 14:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3781473-davita-authorizes-additional-2b-share-repurchase><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DaVita  Board of Directors increased the authorization under the existing share repurchase program by $2B in additional repurchasing authority.\nThe amount of shares authorized to be repurchased under ...</p>\n\n<a href=\"https://seekingalpha.com/news/3781473-davita-authorizes-additional-2b-share-repurchase\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DVA":"达维塔保健"},"source_url":"https://seekingalpha.com/news/3781473-davita-authorizes-additional-2b-share-repurchase","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189235922","content_text":"DaVita  Board of Directors increased the authorization under the existing share repurchase program by $2B in additional repurchasing authority.\nThe amount of shares authorized to be repurchased under the new authorization does not include the amount remaining under the company’s existing share repurchase program authorized on December 10, 2020 .\nSome bearish commentary and rating on the stock by SA contributor who writes: 'The company appears to be overvalued, and there are several challenges facing the company in the future.'","news_type":1,"symbols_score_info":{"DVA":0.9}},"isVote":1,"tweetType":1,"viewCount":1616,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690450573,"gmtCreate":1639703743619,"gmtModify":1639703743744,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/690450573","repostId":"2192194909","repostType":4,"repost":{"id":"2192194909","kind":"highlight","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1639701314,"share":"https://www.laohu8.com/m/news/2192194909?lang=&edition=full","pubTime":"2021-12-17 08:35","market":"us","language":"en","title":"Adagio Therapeutics Continues Its Wild Ride — How Two Tests Led To A Triple-Digit Gain","url":"https://stock-news.laohu8.com/highlight/detail?id=2192194909","media":"Investors","summary":"New analyses suggest Adagio Therapeutics' Covid antibody could still tackle the omicron variant — and ADGI stock soared on Thursday.","content":"<p>New analyses suggest <b><a href=\"https://laohu8.com/S/ADGI\">Adagio Therapeutics</a></b>' Covid antibody could still tackle the omicron variant — and ADGI stock soared on Thursday.</p>\n<p>Two studies from renowned laboratories in the U.S. and France suggest Adagio's experimental antibody-based drug, ADG20, fights omicron-induced Covid, Jefferies analyst Michael Yee wrote in a report to clients. In response, ADGI stock rocketed 106% near 13.10.</p>\n<p>The news is a 180-degree turn from earlier this week when shares plummeted after Adagio said its antibody experienced a huge drop in effectiveness against omicron. Now, Yee says, it appears the Adagio drug is lining up with <b>Vir Biotechnology</b> and <b>GlaxoSmithKline</b>. Also this week, the duo said their antibody could effectively target omicron.</p>\n<p>\"So, maybe Adagio (drug ADG20) is not as bad as previously thought and is in the ballpark of GlaxoSmithKline/Vir which means it has utility and (effectiveness) and has a real role,\" Yee said.</p>\n<h2>ADGI Stock Continues Its Wild Ride</h2>\n<p>Antibody drugs have taken a wild ride on the omicron train.</p>\n<p>Vaccines prompt the body to generate virus-blocking antibodies. Antibody-based treatments, on the other hand, simply infuse or inject a person with the virus blockers.</p>\n<p>But omicron contains numerous mutations to its spike protein, so antibodies find it harder to recognize. Adagio previously said none of omicron's mutations would hurt the effectiveness of its drug. But, on Tuesday, ADGI stock crashed after the company said that theory didn't pan out in further testing.</p>\n<p>\"We said this was a significant surprise because all data suggested their drug should be potent against omicron and even Adagio management said all along (that) all their prior work suggests the conserved binding region and other factors should lead it to be a great antibody against omicron and future variants,\" Yee said.</p>\n<p>The news on Thursday resulted in another flip for ADGI stock, however.</p>\n<p>The laboratories found omicron leads to a 20-40 times reduction in the effectiveness of ADG20 against omicron. That's better than the 300-fold drop Adagio estimated on Tuesday, Yee said. He has a 46 price target on ADGI stock.</p>\n<h2>Other Antibodies Target Omicron</h2>\n<p>Similarly, on Thursday, <b>AstraZeneca</b> said its antibody is less effective against omicron than it is against the original strain. But that drug, dubbed Evusheld, can still target omicron, AstraZeneca said.</p>\n<p>AstraZeneca stock rose 1.87% near 56.70 in midday trading on the stock market today. Vir stock continued a six-day running spree, jumping 8.5% near 56. On Wednesday, Vir stock broke out of a cup-with-handle base with a buy point at 52.95, according to MarketSmith.com.</p>\n<p>Meanwhile, <b><a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a></b> stock crept down 3.5% near 635. The company said its currently authorized antibody regimen loses effectiveness against omicron. But, Regeneron said, its next-generation antibodies can target omicron and delta. Those antibodies don't have authorization, however.</p>\n<p>It's important to note that ADGI stock is lowly rated across IBD Digital measures. Shares have a rock-bottom Relative Strength Rating of 1, putting its 12-month performance in the bottom 1% of all stocks.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adagio Therapeutics Continues Its Wild Ride — How Two Tests Led To A Triple-Digit Gain</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdagio Therapeutics Continues Its Wild Ride — How Two Tests Led To A Triple-Digit Gain\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time\">2021-12-17 08:35</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>New analyses suggest <b><a href=\"https://laohu8.com/S/ADGI\">Adagio Therapeutics</a></b>' Covid antibody could still tackle the omicron variant — and ADGI stock soared on Thursday.</p>\n<p>Two studies from renowned laboratories in the U.S. and France suggest Adagio's experimental antibody-based drug, ADG20, fights omicron-induced Covid, Jefferies analyst Michael Yee wrote in a report to clients. In response, ADGI stock rocketed 106% near 13.10.</p>\n<p>The news is a 180-degree turn from earlier this week when shares plummeted after Adagio said its antibody experienced a huge drop in effectiveness against omicron. Now, Yee says, it appears the Adagio drug is lining up with <b>Vir Biotechnology</b> and <b>GlaxoSmithKline</b>. Also this week, the duo said their antibody could effectively target omicron.</p>\n<p>\"So, maybe Adagio (drug ADG20) is not as bad as previously thought and is in the ballpark of GlaxoSmithKline/Vir which means it has utility and (effectiveness) and has a real role,\" Yee said.</p>\n<h2>ADGI Stock Continues Its Wild Ride</h2>\n<p>Antibody drugs have taken a wild ride on the omicron train.</p>\n<p>Vaccines prompt the body to generate virus-blocking antibodies. Antibody-based treatments, on the other hand, simply infuse or inject a person with the virus blockers.</p>\n<p>But omicron contains numerous mutations to its spike protein, so antibodies find it harder to recognize. Adagio previously said none of omicron's mutations would hurt the effectiveness of its drug. But, on Tuesday, ADGI stock crashed after the company said that theory didn't pan out in further testing.</p>\n<p>\"We said this was a significant surprise because all data suggested their drug should be potent against omicron and even Adagio management said all along (that) all their prior work suggests the conserved binding region and other factors should lead it to be a great antibody against omicron and future variants,\" Yee said.</p>\n<p>The news on Thursday resulted in another flip for ADGI stock, however.</p>\n<p>The laboratories found omicron leads to a 20-40 times reduction in the effectiveness of ADG20 against omicron. That's better than the 300-fold drop Adagio estimated on Tuesday, Yee said. He has a 46 price target on ADGI stock.</p>\n<h2>Other Antibodies Target Omicron</h2>\n<p>Similarly, on Thursday, <b>AstraZeneca</b> said its antibody is less effective against omicron than it is against the original strain. But that drug, dubbed Evusheld, can still target omicron, AstraZeneca said.</p>\n<p>AstraZeneca stock rose 1.87% near 56.70 in midday trading on the stock market today. Vir stock continued a six-day running spree, jumping 8.5% near 56. On Wednesday, Vir stock broke out of a cup-with-handle base with a buy point at 52.95, according to MarketSmith.com.</p>\n<p>Meanwhile, <b><a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a></b> stock crept down 3.5% near 635. The company said its currently authorized antibody regimen loses effectiveness against omicron. But, Regeneron said, its next-generation antibodies can target omicron and delta. Those antibodies don't have authorization, however.</p>\n<p>It's important to note that ADGI stock is lowly rated across IBD Digital measures. Shares have a rock-bottom Relative Strength Rating of 1, putting its 12-month performance in the bottom 1% of all stocks.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4539":"次新股"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192194909","content_text":"New analyses suggest Adagio Therapeutics' Covid antibody could still tackle the omicron variant — and ADGI stock soared on Thursday.\nTwo studies from renowned laboratories in the U.S. and France suggest Adagio's experimental antibody-based drug, ADG20, fights omicron-induced Covid, Jefferies analyst Michael Yee wrote in a report to clients. In response, ADGI stock rocketed 106% near 13.10.\nThe news is a 180-degree turn from earlier this week when shares plummeted after Adagio said its antibody experienced a huge drop in effectiveness against omicron. Now, Yee says, it appears the Adagio drug is lining up with Vir Biotechnology and GlaxoSmithKline. Also this week, the duo said their antibody could effectively target omicron.\n\"So, maybe Adagio (drug ADG20) is not as bad as previously thought and is in the ballpark of GlaxoSmithKline/Vir which means it has utility and (effectiveness) and has a real role,\" Yee said.\nADGI Stock Continues Its Wild Ride\nAntibody drugs have taken a wild ride on the omicron train.\nVaccines prompt the body to generate virus-blocking antibodies. Antibody-based treatments, on the other hand, simply infuse or inject a person with the virus blockers.\nBut omicron contains numerous mutations to its spike protein, so antibodies find it harder to recognize. Adagio previously said none of omicron's mutations would hurt the effectiveness of its drug. But, on Tuesday, ADGI stock crashed after the company said that theory didn't pan out in further testing.\n\"We said this was a significant surprise because all data suggested their drug should be potent against omicron and even Adagio management said all along (that) all their prior work suggests the conserved binding region and other factors should lead it to be a great antibody against omicron and future variants,\" Yee said.\nThe news on Thursday resulted in another flip for ADGI stock, however.\nThe laboratories found omicron leads to a 20-40 times reduction in the effectiveness of ADG20 against omicron. That's better than the 300-fold drop Adagio estimated on Tuesday, Yee said. He has a 46 price target on ADGI stock.\nOther Antibodies Target Omicron\nSimilarly, on Thursday, AstraZeneca said its antibody is less effective against omicron than it is against the original strain. But that drug, dubbed Evusheld, can still target omicron, AstraZeneca said.\nAstraZeneca stock rose 1.87% near 56.70 in midday trading on the stock market today. Vir stock continued a six-day running spree, jumping 8.5% near 56. On Wednesday, Vir stock broke out of a cup-with-handle base with a buy point at 52.95, according to MarketSmith.com.\nMeanwhile, Regeneron Pharmaceuticals stock crept down 3.5% near 635. The company said its currently authorized antibody regimen loses effectiveness against omicron. But, Regeneron said, its next-generation antibodies can target omicron and delta. Those antibodies don't have authorization, however.\nIt's important to note that ADGI stock is lowly rated across IBD Digital measures. Shares have a rock-bottom Relative Strength Rating of 1, putting its 12-month performance in the bottom 1% of all stocks.","news_type":1,"symbols_score_info":{"ADGI":0.9}},"isVote":1,"tweetType":1,"viewCount":1923,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690059971,"gmtCreate":1639615627130,"gmtModify":1639615627236,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/690059971","repostId":"1172070133","repostType":4,"repost":{"id":"1172070133","kind":"news","pubTimestamp":1639621250,"share":"https://www.laohu8.com/m/news/1172070133?lang=&edition=full","pubTime":"2021-12-16 10:20","market":"us","language":"en","title":"All the doves at the Fed have become hawks","url":"https://stock-news.laohu8.com/highlight/detail?id=1172070133","media":"MarketWatch","summary":"The U.S. central bank charts a completely new course to attack inflation rather than continue to wai","content":"<p>The U.S. central bank charts a completely new course to attack inflation rather than continue to wait it out</p>\n<p><img src=\"https://static.tigerbbs.com/ba1b24817095f66e1cbf69b3dd7a4ad8\" tg-width=\"700\" tg-height=\"399\" referrerpolicy=\"no-referrer\"></p>\n<p>The big news from the Federal Reserve’s meeting Wednesday wasn’t that it’ll stop buying bonds to stimulate the economy&nbsp;or that it’s now signaling three increases in its benchmark lending rate in 2022. Those short-term policy decisions had been well-telegraphed by Fed officials over the past month.</p>\n<p>No, the big surprise is that the gargantuan, change-averse Fed has turned 180 degrees in its view of inflation.</p>\n<p>The Fed’s statement&nbsp;Wednesday and the accompanying materials show that the doves — the policy makers who generally believe that the risk of inflation is overblown — have completely surrendered. Everyone’s a hawk now. There are no doves at the Fed anymore.</p>\n<p>Fed monetary-policy makers unanimously agree that fighting inflation is their No. 1 job. They may disagree on the tactics or the timing, but not on the strategy of vanquishing inflation soon. The Fed is on a war footing, and inflation is the enemy.</p>\n<p>For 30 years, the doves had been right: Inflation wasn’t the biggest threat to the economy; unemployment was. The doves fought an ultimately successful battle to force the Federal Reserve to consider the very real costs that unemployment forces upon society and the many individuals whom the economy was leaving behind.</p>\n<p>But now effects of the coronavirus pandemic have forced even the doves to accept that inflation is a bigger threat than unemployment. That’s a huge change in an institution that doesn’t like change.</p>\n<p>How do we know the doves have metamorphosed into hawks? Look at the dot plot, a chart the Fed releases every three months that shows the anonymous individual forecasts of each monetary-policy maker for the level of the federal funds rate at the ends of the next several years.</p>\n<p>Most analysts correctly focus on the median forecast for the coming year, but I’d like to redirect your attention briefly to the medium-term forecasts of the outliers, the most hawkish and dovish members of the Fed, to show how much the battlefield inside the Fed has changed since that horrendous consumer-price-index reading of Nov. 10. That report changed everything at the Fed.</p>\n<p><img src=\"https://static.tigerbbs.com/fc738ce106c9173e3b5b93bf435f87f7\" tg-width=\"700\" tg-height=\"644\" referrerpolicy=\"no-referrer\"></p>\n<p>In the latest forecasts released Wednesday, the most hawkish members raised their medium-term forecasts modestly from 1.63% to 2.13% at the end of 2023, and from 2.63% to 3.13% at the end of 2024. The five most hawkish members now think the Fed will have to push the fed funds rate above its assumed long-run equilibrium of 2.5%.</p>\n<p>But the doves completely tore up their previous forecasts. The five most dovish members were forecasting between zero and two rate hikes by the end of 2023, but now they expect four or five. By the end of 2024, they had been forecasting between two and four rate hikes; now they expect seven.</p>\n<p>Clearly, even the most dovish Fed officials now believe&nbsp;the fed funds rate must go up a lot to vanquish inflation. Before, they thought inflation would come down all by itself.</p>\n<p>This means that inflation no longer gets the benefit of the doubt. It’s been proven guilty, and even the doves will prosecute the war until victory is won. For the inflation doves at the Fed, Nov. 10, 2021, was bit of like Dec. 7, 1941: Time to go to war.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>All the doves at the Fed have become hawks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAll the doves at the Fed have become hawks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-16 10:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/all-the-doves-at-the-fed-have-become-hawks-11639613760?mod=mw_latestnews><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. central bank charts a completely new course to attack inflation rather than continue to wait it out\n\nThe big news from the Federal Reserve’s meeting Wednesday wasn’t that it’ll stop buying ...</p>\n\n<a href=\"https://www.marketwatch.com/story/all-the-doves-at-the-fed-have-become-hawks-11639613760?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://www.marketwatch.com/story/all-the-doves-at-the-fed-have-become-hawks-11639613760?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172070133","content_text":"The U.S. central bank charts a completely new course to attack inflation rather than continue to wait it out\n\nThe big news from the Federal Reserve’s meeting Wednesday wasn’t that it’ll stop buying bonds to stimulate the economy or that it’s now signaling three increases in its benchmark lending rate in 2022. Those short-term policy decisions had been well-telegraphed by Fed officials over the past month.\nNo, the big surprise is that the gargantuan, change-averse Fed has turned 180 degrees in its view of inflation.\nThe Fed’s statement Wednesday and the accompanying materials show that the doves — the policy makers who generally believe that the risk of inflation is overblown — have completely surrendered. Everyone’s a hawk now. There are no doves at the Fed anymore.\nFed monetary-policy makers unanimously agree that fighting inflation is their No. 1 job. They may disagree on the tactics or the timing, but not on the strategy of vanquishing inflation soon. The Fed is on a war footing, and inflation is the enemy.\nFor 30 years, the doves had been right: Inflation wasn’t the biggest threat to the economy; unemployment was. The doves fought an ultimately successful battle to force the Federal Reserve to consider the very real costs that unemployment forces upon society and the many individuals whom the economy was leaving behind.\nBut now effects of the coronavirus pandemic have forced even the doves to accept that inflation is a bigger threat than unemployment. That’s a huge change in an institution that doesn’t like change.\nHow do we know the doves have metamorphosed into hawks? Look at the dot plot, a chart the Fed releases every three months that shows the anonymous individual forecasts of each monetary-policy maker for the level of the federal funds rate at the ends of the next several years.\nMost analysts correctly focus on the median forecast for the coming year, but I’d like to redirect your attention briefly to the medium-term forecasts of the outliers, the most hawkish and dovish members of the Fed, to show how much the battlefield inside the Fed has changed since that horrendous consumer-price-index reading of Nov. 10. That report changed everything at the Fed.\n\nIn the latest forecasts released Wednesday, the most hawkish members raised their medium-term forecasts modestly from 1.63% to 2.13% at the end of 2023, and from 2.63% to 3.13% at the end of 2024. The five most hawkish members now think the Fed will have to push the fed funds rate above its assumed long-run equilibrium of 2.5%.\nBut the doves completely tore up their previous forecasts. The five most dovish members were forecasting between zero and two rate hikes by the end of 2023, but now they expect four or five. By the end of 2024, they had been forecasting between two and four rate hikes; now they expect seven.\nClearly, even the most dovish Fed officials now believe the fed funds rate must go up a lot to vanquish inflation. Before, they thought inflation would come down all by itself.\nThis means that inflation no longer gets the benefit of the doubt. It’s been proven guilty, and even the doves will prosecute the war until victory is won. For the inflation doves at the Fed, Nov. 10, 2021, was bit of like Dec. 7, 1941: Time to go to war.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":2311,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607695836,"gmtCreate":1639530829485,"gmtModify":1639530829588,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/607695836","repostId":"1129773083","repostType":4,"isVote":1,"tweetType":1,"viewCount":2646,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604472686,"gmtCreate":1639442680885,"gmtModify":1639442680992,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604472686","repostId":"2191811539","repostType":4,"isVote":1,"tweetType":1,"viewCount":2074,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604675566,"gmtCreate":1639395534696,"gmtModify":1639395534808,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/604675566","repostId":"1131710846","repostType":4,"repost":{"id":"1131710846","kind":"news","pubTimestamp":1639393441,"share":"https://www.laohu8.com/m/news/1131710846?lang=&edition=full","pubTime":"2021-12-13 19:04","market":"fut","language":"en","title":"Stock Futures Edge Up After S&P 500 Hits Record","url":"https://stock-news.laohu8.com/highlight/detail?id=1131710846","media":"WSJ","summary":"U.S. stock futures pointed to muted gains for major indexes ahead of a busy week of central-bank dec","content":"<p>U.S. stock futures pointed to muted gains for major indexes ahead of a busy week of central-bank decisions in major economies.</p>\n<p>Futures for the S&amp;P 500 rose 0.2% Monday, after the benchmark gauge closed last week at its67th record high of 2021. Contracts for the Dow Jones Industrial Average, which sits just shy of an all-time high, also ticked up 0.2%, as did futures for the technology-heavy Nasdaq-100.</p>\n<p>In the bond market, the yield on benchmark 10-year Treasury notes ticked up to 1.492% Monday from 1.487% Friday. Yields move in the opposite direction to bond prices.</p>\n<p>Investors are sitting tight ahead of a monetary-policy decision by the Federal Reserve and announcements from the Bank of England, European Central Bank and&nbsp;Bank of Japan&nbsp;later in the week. The Fed is expected to accelerate the pace at which it is paring its bond-buying program and to signal that it will raise interest rates next year to tap the brakes on inflation. Data published Friday showed consumer prices increased in November at the&nbsp;fastest annual rate since 1982.</p>\n<p>Gregory Perdon, co-chief investment officer at&nbsp;Arbuthnot Latham,said he expects stocks to keep rising even as the Fed tightens monetary policy.</p>\n<p>“The classic textbook would be rates up, stocks down,” Mr. Perdon said. “The reality is there’s so much liquidity out there, there’s so much demand to get a return on assets that ultimately we’re going to have to have a much…more aggressive tightening to knock stocks.”</p>\n<p>Commodity prices rose. Brent-crude futures, the benchmark in international energy markets, ticked up 0.5% to $75.53 a barrel. Prices snapped a six-week losing streak Friday, recovering some ground shed when the Omicron variant threatened to hit oil demand.</p>\n<p>European natural-gas prices jumped more than 8% Monday. Supplies of gas, a key heating and power-generation fuel in Europe, are well below their recent average for the time of year, raising concerns stockpiles will run low as cold weather lifts demand. U.S. natural-gas futures rose 1.9% to $4 per million British thermal units.</p>\n<p>Turkey’s lira slumped 4% to trade at 14.46 to the dollar ahead of an expected rate cut by the central bank on Thursday. The Central Bank of the Republic of Turkey has bowed to pressure from President Recep Tayyip Erdogan to lower borrowing costs this year in the face of rapid inflation, hitting the currency hard.</p>\n<p>Overseas stock markets were mixed. The Stoxx Europe 600 edged up 0.1%, led higher by shares of basic-resources, auto and oil-and-gas companies. Among individual movers,Vifor Pharmajumped more than 15% after the Swiss pharmaceutical firm said it was in talks to be bought by Australia’s CSL.</p>\n<p>Japan’s Nikkei 225 rose 0.7%, the Shanghai Composite Index added 0.4% and Hong Kong’s Hang Seng slipped 0.2%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Futures Edge Up After S&P 500 Hits Record</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Futures Edge Up After S&P 500 Hits Record\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 19:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/global-stock-markets-dow-update-12-13-2021-11639384564?mod=hp_lead_pos1><strong>WSJ</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>U.S. stock futures pointed to muted gains for major indexes ahead of a busy week of central-bank decisions in major economies.\nFutures for the S&P 500 rose 0.2% Monday, after the benchmark gauge ...</p>\n\n<a href=\"https://www.wsj.com/articles/global-stock-markets-dow-update-12-13-2021-11639384564?mod=hp_lead_pos1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"source_url":"https://www.wsj.com/articles/global-stock-markets-dow-update-12-13-2021-11639384564?mod=hp_lead_pos1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131710846","content_text":"U.S. stock futures pointed to muted gains for major indexes ahead of a busy week of central-bank decisions in major economies.\nFutures for the S&P 500 rose 0.2% Monday, after the benchmark gauge closed last week at its67th record high of 2021. Contracts for the Dow Jones Industrial Average, which sits just shy of an all-time high, also ticked up 0.2%, as did futures for the technology-heavy Nasdaq-100.\nIn the bond market, the yield on benchmark 10-year Treasury notes ticked up to 1.492% Monday from 1.487% Friday. Yields move in the opposite direction to bond prices.\nInvestors are sitting tight ahead of a monetary-policy decision by the Federal Reserve and announcements from the Bank of England, European Central Bank and Bank of Japan later in the week. The Fed is expected to accelerate the pace at which it is paring its bond-buying program and to signal that it will raise interest rates next year to tap the brakes on inflation. Data published Friday showed consumer prices increased in November at the fastest annual rate since 1982.\nGregory Perdon, co-chief investment officer at Arbuthnot Latham,said he expects stocks to keep rising even as the Fed tightens monetary policy.\n“The classic textbook would be rates up, stocks down,” Mr. Perdon said. “The reality is there’s so much liquidity out there, there’s so much demand to get a return on assets that ultimately we’re going to have to have a much…more aggressive tightening to knock stocks.”\nCommodity prices rose. Brent-crude futures, the benchmark in international energy markets, ticked up 0.5% to $75.53 a barrel. Prices snapped a six-week losing streak Friday, recovering some ground shed when the Omicron variant threatened to hit oil demand.\nEuropean natural-gas prices jumped more than 8% Monday. Supplies of gas, a key heating and power-generation fuel in Europe, are well below their recent average for the time of year, raising concerns stockpiles will run low as cold weather lifts demand. U.S. natural-gas futures rose 1.9% to $4 per million British thermal units.\nTurkey’s lira slumped 4% to trade at 14.46 to the dollar ahead of an expected rate cut by the central bank on Thursday. The Central Bank of the Republic of Turkey has bowed to pressure from President Recep Tayyip Erdogan to lower borrowing costs this year in the face of rapid inflation, hitting the currency hard.\nOverseas stock markets were mixed. The Stoxx Europe 600 edged up 0.1%, led higher by shares of basic-resources, auto and oil-and-gas companies. Among individual movers,Vifor Pharmajumped more than 15% after the Swiss pharmaceutical firm said it was in talks to be bought by Australia’s CSL.\nJapan’s Nikkei 225 rose 0.7%, the Shanghai Composite Index added 0.4% and Hong Kong’s Hang Seng slipped 0.2%.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9,"BZmain":0.9,"CLmain":0.9,"ESmain":0.9,"NQmain":0.9,"YMmain":0.9}},"isVote":1,"tweetType":1,"viewCount":2832,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604301439,"gmtCreate":1639325093032,"gmtModify":1639325093141,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/604301439","repostId":"2190719536","repostType":4,"isVote":1,"tweetType":1,"viewCount":2028,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605624338,"gmtCreate":1639155725026,"gmtModify":1639155782282,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605624338","repostId":"1165282830","repostType":4,"repost":{"id":"1165282830","kind":"news","pubTimestamp":1639148461,"share":"https://www.laohu8.com/m/news/1165282830?lang=&edition=full","pubTime":"2021-12-10 23:01","market":"us","language":"en","title":"Tesla stops taking Model S and Model X orders outside North America","url":"https://stock-news.laohu8.com/highlight/detail?id=1165282830","media":"Electrek","summary":"Tesla announced to potential buyers today that it stopped taking new Model S and Model X orders outs","content":"<p>Tesla announced to potential buyers today that it stopped taking new Model S and Model X orders outside North America.</p>\n<p>It now expects deliveries in other markets to start during the second half of 2022.</p>\n<p>The news comes from an email that Tesla started sending out to people who have Model S and Model X vehicles on order in Europe.</p>\n<p>Tesla writes in the email that it is not accepting any new orders (translated from German):</p>\n<blockquote>\n In order to expedite the delivery of existing orders, including your Model X order, as much as possible, we are currently no longer accepting new orders for the Model S and Model X from markets outside of North America.\n</blockquote>\n<p>This is in response to Tesla likely having a large backlog of Model S/X orders in Europe and other markets, where there has been no new Model S/X shipment in a year.</p>\n<p>Tesla shut down Model S and Model X production in January of last year to update the vehicles.</p>\n<p>During that year, the automaker kept taking new orders, but production was delayed with new Model S starting to slowly come off the assembly line in June and&nbsp;Model X in October.</p>\n<p>Tesla is still catching up to the backlog in North America while new orders kept coming in from Europe and Asia.</p>\n<p>In the email, Tesla says that it now aims to deliver the first Model S and Model X in Europe during the second half of next year:</p>\n<blockquote>\n Your Model X is getting closer to delivery. We currently expect shipments outside of North America to begin in the second half of 2022.\n</blockquote>\n<p>This means that Europe would be without Model S and Model X for a year and a half.</p>\n<p>Here’s the email in full:</p>\n<blockquote>\n Hello [redacted],\n</blockquote>\n<blockquote>\n We are contacting you regarding the timing of your Model X order. As we expand production capacity, the launch dates for markets outside of North America have been postponed. We will inform you of the delivery times through your Tesla account when production begins.\n</blockquote>\n<blockquote>\n Your Model X is getting closer to delivery. We currently expect shipments outside of North America to begin in the second half of 2022.\n</blockquote>\n<blockquote>\n In order to expedite the delivery of existing orders, including your Model X order, as much as possible, we are currently no longer accepting new orders for the Model S and Model X from markets outside of North America.\n</blockquote>\n<blockquote>\n The price of your Model X will continue to be the same as it was when you placed your order, unless your vehicle configuration has been changed. To apply your order fee to another model, or to receive a full refund, request a call to speak directly to a Tesla representative.\n</blockquote>\n<blockquote>\n We apologize for any inconvenience this may cause.\n</blockquote>\n<blockquote>\n Kind regards,\n</blockquote>\n<blockquote>\n Your Tesla Team Testa\n</blockquote>","source":"lsy1627037122897","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla stops taking Model S and Model X orders outside North America</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla stops taking Model S and Model X orders outside North America\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-10 23:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://electrek.co/2021/12/10/tesla-stops-taking-model-s-x-orders-outside-north-america/><strong>Electrek</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tesla announced to potential buyers today that it stopped taking new Model S and Model X orders outside North America.\nIt now expects deliveries in other markets to start during the second half of ...</p>\n\n<a href=\"https://electrek.co/2021/12/10/tesla-stops-taking-model-s-x-orders-outside-north-america/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://electrek.co/2021/12/10/tesla-stops-taking-model-s-x-orders-outside-north-america/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165282830","content_text":"Tesla announced to potential buyers today that it stopped taking new Model S and Model X orders outside North America.\nIt now expects deliveries in other markets to start during the second half of 2022.\nThe news comes from an email that Tesla started sending out to people who have Model S and Model X vehicles on order in Europe.\nTesla writes in the email that it is not accepting any new orders (translated from German):\n\n In order to expedite the delivery of existing orders, including your Model X order, as much as possible, we are currently no longer accepting new orders for the Model S and Model X from markets outside of North America.\n\nThis is in response to Tesla likely having a large backlog of Model S/X orders in Europe and other markets, where there has been no new Model S/X shipment in a year.\nTesla shut down Model S and Model X production in January of last year to update the vehicles.\nDuring that year, the automaker kept taking new orders, but production was delayed with new Model S starting to slowly come off the assembly line in June and Model X in October.\nTesla is still catching up to the backlog in North America while new orders kept coming in from Europe and Asia.\nIn the email, Tesla says that it now aims to deliver the first Model S and Model X in Europe during the second half of next year:\n\n Your Model X is getting closer to delivery. We currently expect shipments outside of North America to begin in the second half of 2022.\n\nThis means that Europe would be without Model S and Model X for a year and a half.\nHere’s the email in full:\n\n Hello [redacted],\n\n\n We are contacting you regarding the timing of your Model X order. As we expand production capacity, the launch dates for markets outside of North America have been postponed. We will inform you of the delivery times through your Tesla account when production begins.\n\n\n Your Model X is getting closer to delivery. We currently expect shipments outside of North America to begin in the second half of 2022.\n\n\n In order to expedite the delivery of existing orders, including your Model X order, as much as possible, we are currently no longer accepting new orders for the Model S and Model X from markets outside of North America.\n\n\n The price of your Model X will continue to be the same as it was when you placed your order, unless your vehicle configuration has been changed. To apply your order fee to another model, or to receive a full refund, request a call to speak directly to a Tesla representative.\n\n\n We apologize for any inconvenience this may cause.\n\n\n Kind regards,\n\n\n Your Tesla Team Testa","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":2609,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602540202,"gmtCreate":1639046819835,"gmtModify":1639046819980,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/602540202","repostId":"1128116582","repostType":4,"isVote":1,"tweetType":1,"viewCount":677,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602014612,"gmtCreate":1638939503237,"gmtModify":1638939503339,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/602014612","repostId":"1110034472","repostType":4,"repost":{"id":"1110034472","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638934503,"share":"https://www.laohu8.com/m/news/1110034472?lang=&edition=full","pubTime":"2021-12-08 11:35","market":"us","language":"en","title":"Alibaba shares fell nearly 5% in Hong Kong market","url":"https://stock-news.laohu8.com/highlight/detail?id=1110034472","media":"Tiger Newspress","summary":"Alibaba shares fell nearly 5% in Hong Kong market.\nThe stock rose more than 12% on Tuesday.","content":"<p>Alibaba&nbsp;shares&nbsp;fell&nbsp;nearly&nbsp;5%&nbsp;in&nbsp;Hong&nbsp;Kong&nbsp;market.</p>\n<p>The&nbsp;stock&nbsp;rose&nbsp;more&nbsp;than&nbsp;12%&nbsp;on&nbsp;Tuesday.<img src=\"https://static.tigerbbs.com/7164e9b37a74a667396e8d0d739f70b5\" tg-width=\"708\" tg-height=\"600\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alibaba shares fell nearly 5% in Hong Kong market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlibaba shares fell nearly 5% in Hong Kong market\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-08 11:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Alibaba&nbsp;shares&nbsp;fell&nbsp;nearly&nbsp;5%&nbsp;in&nbsp;Hong&nbsp;Kong&nbsp;market.</p>\n<p>The&nbsp;stock&nbsp;rose&nbsp;more&nbsp;than&nbsp;12%&nbsp;on&nbsp;Tuesday.<img src=\"https://static.tigerbbs.com/7164e9b37a74a667396e8d0d739f70b5\" tg-width=\"708\" tg-height=\"600\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09988":"阿里巴巴-W","BABA":"阿里巴巴"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1110034472","content_text":"Alibaba shares fell nearly 5% in Hong Kong market.\nThe stock rose more than 12% on Tuesday.","news_type":1,"symbols_score_info":{"09988":0.9,"BABA":0.9}},"isVote":1,"tweetType":1,"viewCount":881,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606912472,"gmtCreate":1638808613038,"gmtModify":1638808613175,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/606912472","repostId":"1167580246","repostType":4,"repost":{"id":"1167580246","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638802452,"share":"https://www.laohu8.com/m/news/1167580246?lang=&edition=full","pubTime":"2021-12-06 22:54","market":"us","language":"en","title":"Semiconductor stocks dipped in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1167580246","media":"Tiger Newspress","summary":"Semiconductor stocks dipped in morning trading.Nvidia,TSMC,ASML,AMD,Xilinx,Globalfoundries and ON Se","content":"<p>Semiconductor stocks dipped in morning trading.Nvidia,TSMC,ASML,AMD,Xilinx,Globalfoundries&nbsp;and&nbsp;ON&nbsp;Semiconductor fell between 2% and 7%.</p>\n<p><img src=\"https://static.tigerbbs.com/8fd417bf4091570cb848a432d4946ce4\" tg-width=\"400\" tg-height=\"714\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Semiconductor stocks dipped in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSemiconductor stocks dipped in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-06 22:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Semiconductor stocks dipped in morning trading.Nvidia,TSMC,ASML,AMD,Xilinx,Globalfoundries&nbsp;and&nbsp;ON&nbsp;Semiconductor fell between 2% and 7%.</p>\n<p><img src=\"https://static.tigerbbs.com/8fd417bf4091570cb848a432d4946ce4\" tg-width=\"400\" tg-height=\"714\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MU":"美光科技","ASML":"阿斯麦","ON":"安森美半导体","QCOM":"高通","GFS":"GLOBALFOUNDRIES Inc.","NVDA":"英伟达","AMD":"美国超微公司","MRVL":"迈威尔科技","TSM":"台积电","ADI":"亚德诺","TXN":"德州仪器"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167580246","content_text":"Semiconductor stocks dipped in morning trading.Nvidia,TSMC,ASML,AMD,Xilinx,Globalfoundries and ON Semiconductor fell between 2% and 7%.","news_type":1,"symbols_score_info":{"ADI":0.9,"AMD":0.9,"ASML":0.9,"GFS":0.9,"MRVL":0.9,"MU":0.9,"NVDA":0.9,"ON":0.9,"QCOM":0.9,"TSM":0.9,"TXN":0.9,"XLNX":0.9}},"isVote":1,"tweetType":1,"viewCount":635,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601166584,"gmtCreate":1638498825733,"gmtModify":1638498825733,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/601166584","repostId":"1137450856","repostType":4,"isVote":1,"tweetType":1,"viewCount":1017,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609477956,"gmtCreate":1638322081879,"gmtModify":1638322081950,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/609477956","repostId":"2188535363","repostType":4,"isVote":1,"tweetType":1,"viewCount":359,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609699402,"gmtCreate":1638274629509,"gmtModify":1638274629576,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609699402","repostId":"1136264859","repostType":4,"repost":{"id":"1136264859","kind":"news","pubTimestamp":1638272133,"share":"https://www.laohu8.com/m/news/1136264859?lang=&edition=full","pubTime":"2021-11-30 19:35","market":"us","language":"en","title":"Roku’s Beaten-Down Stock Is Still a Winner, Analysts Say","url":"https://stock-news.laohu8.com/highlight/detail?id=1136264859","media":"Barrons","summary":"Roku shares have floundered in recent weeks as the stay-at-home trade unraveled. But a few analysts ","content":"<p>Roku&nbsp;shares have floundered in recent weeks as the stay-at-home trade unraveled. But a few analysts say the dip will prove temporary.</p>\n<p>Benchmark analyst Daniel Kurnos wrote in a note on Monday that sentiment on Wall Street has been negative, to say the least, with Roku’s stock price (ticker: ROKU) cut in half from its one-year intraday high. Analysts have been taking a less upbeat view of Roku’s postpandemic prospects, but Kurnos also noted some tension ahead of a Dec. 9 deadline for Roku and&nbsp;Alphabet’s&nbsp;(GOOGL) YouTube to reach a deal to keep the app on the Roku platform.</p>\n<p>Roku stock, which Kurnos rates at Buy, was down 1.7% to $231.28 on Monday. His target for the stock price is $525, which implies a gain of nearly127%, for those counting.</p>\n<p>“We think this is an ideal setup for the stock, especially since our channel checks indicate a much healthier in-stock level of Roku TVs at both&nbsp;Walmart&nbsp;and&nbsp;Best Buy&nbsp;than feared, while we think a Google-Roku resolution could be in the offing even if a temporary blackout occurs,” Kurnos wrote.</p>\n<p>While he thinks Roku could temporarily drop the YouTube app, he argued there is too much at stake for both parties not to find a compromise, possibly before the end of the year.</p>\n<p>“Not only would this be a positive catalyst for the stock but it would also lessen the fears around a potential Roku-Amazon showdown in the future,” Kurnos wrote.</p>\n<p>Roku sells devices that turn televisions into smart TVs, accessing the Roku platform via the internet. It has deals in place with apps, in some cases getting a cut of subscriptions and advertising dollars spent on its platform.</p>\n<p>Kurnos likened the situation to the spring of 2020, when those betting against Roku stock argued the company would see increased competition and was losing leverage in its negotiations for streaming services. The company later reached deals with&nbsp;AT&amp;T’s&nbsp;HBO Max and&nbsp;Comcast’s&nbsp;Peacock services.</p>\n<p>“Roku has one of the most advanced, self-contained ecosystems within streaming, and thus we expect them to be a share gainer, with levers to pull by making additional options available only if participants utilize the OneView platform, for example,” he wrote, referring to Roku’s OneView ad-buying platform.</p>\n<p>Also on Monday, Bank of America Securities analyst Ruplu Bhattacharya cut his price target to $360 from $400 but maintained a Buy rating. Near-term headwinds the company faces—think supply chain and logistics challenges and lower spending from advertisers in areas such as consumer packaged goods, car manufacturing, and restaurants—are transitory, he said.</p>\n<p>Roku’s competitive advantages remain intact, Bhattacharya said.</p>\n<p>“In the long-term, we expect Roku revenues to benefit from active account growth driven by geographic expansion into international markets, and increasing content,” Bhattacharya wrote. “In addition, Advertising revenues should continue to benefit from the shift of Ad spend from Linear TV to [over-the-top], as well as from Roku’s proprietary viewership data and OneView’s omni channel capabilities.”</p>\n<p>D.A. Davidson analysts called Roku stock their top pick for the 2021 holiday season. They reiterated a Buy rating and $550 price target, saying supply-chain challenges could benefit Roku, in the sense that subscriptions to streaming-services such as Disney+, HBO Max, and&nbsp;Netflix&nbsp;could be popular gifts.</p>\n<p>“We believe this could benefit Roku on multiple fronts,” they wrote.</p>\n<p>They argued Roku’s strong position as a smart-TV operating-system provider could mean users who get streaming-service gift cards could sign up on the Roku platform, driving revenue to Roku. Plus, if streaming services want to steer potential gift givers to their own offerings, such firms might look to advertise on Roku’s platform, they said.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roku’s Beaten-Down Stock Is Still a Winner, Analysts Say</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoku’s Beaten-Down Stock Is Still a Winner, Analysts Say\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 19:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/roku-stock-price-buy-outlook-51638229560?mod=hp_LATEST><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Roku shares have floundered in recent weeks as the stay-at-home trade unraveled. But a few analysts say the dip will prove temporary.\nBenchmark analyst Daniel Kurnos wrote in a note on Monday that ...</p>\n\n<a href=\"https://www.barrons.com/articles/roku-stock-price-buy-outlook-51638229560?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ROKU":"Roku Inc"},"source_url":"https://www.barrons.com/articles/roku-stock-price-buy-outlook-51638229560?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136264859","content_text":"Roku shares have floundered in recent weeks as the stay-at-home trade unraveled. But a few analysts say the dip will prove temporary.\nBenchmark analyst Daniel Kurnos wrote in a note on Monday that sentiment on Wall Street has been negative, to say the least, with Roku’s stock price (ticker: ROKU) cut in half from its one-year intraday high. Analysts have been taking a less upbeat view of Roku’s postpandemic prospects, but Kurnos also noted some tension ahead of a Dec. 9 deadline for Roku and Alphabet’s (GOOGL) YouTube to reach a deal to keep the app on the Roku platform.\nRoku stock, which Kurnos rates at Buy, was down 1.7% to $231.28 on Monday. His target for the stock price is $525, which implies a gain of nearly127%, for those counting.\n“We think this is an ideal setup for the stock, especially since our channel checks indicate a much healthier in-stock level of Roku TVs at both Walmart and Best Buy than feared, while we think a Google-Roku resolution could be in the offing even if a temporary blackout occurs,” Kurnos wrote.\nWhile he thinks Roku could temporarily drop the YouTube app, he argued there is too much at stake for both parties not to find a compromise, possibly before the end of the year.\n“Not only would this be a positive catalyst for the stock but it would also lessen the fears around a potential Roku-Amazon showdown in the future,” Kurnos wrote.\nRoku sells devices that turn televisions into smart TVs, accessing the Roku platform via the internet. It has deals in place with apps, in some cases getting a cut of subscriptions and advertising dollars spent on its platform.\nKurnos likened the situation to the spring of 2020, when those betting against Roku stock argued the company would see increased competition and was losing leverage in its negotiations for streaming services. The company later reached deals with AT&T’s HBO Max and Comcast’s Peacock services.\n“Roku has one of the most advanced, self-contained ecosystems within streaming, and thus we expect them to be a share gainer, with levers to pull by making additional options available only if participants utilize the OneView platform, for example,” he wrote, referring to Roku’s OneView ad-buying platform.\nAlso on Monday, Bank of America Securities analyst Ruplu Bhattacharya cut his price target to $360 from $400 but maintained a Buy rating. Near-term headwinds the company faces—think supply chain and logistics challenges and lower spending from advertisers in areas such as consumer packaged goods, car manufacturing, and restaurants—are transitory, he said.\nRoku’s competitive advantages remain intact, Bhattacharya said.\n“In the long-term, we expect Roku revenues to benefit from active account growth driven by geographic expansion into international markets, and increasing content,” Bhattacharya wrote. “In addition, Advertising revenues should continue to benefit from the shift of Ad spend from Linear TV to [over-the-top], as well as from Roku’s proprietary viewership data and OneView’s omni channel capabilities.”\nD.A. Davidson analysts called Roku stock their top pick for the 2021 holiday season. They reiterated a Buy rating and $550 price target, saying supply-chain challenges could benefit Roku, in the sense that subscriptions to streaming-services such as Disney+, HBO Max, and Netflix could be popular gifts.\n“We believe this could benefit Roku on multiple fronts,” they wrote.\nThey argued Roku’s strong position as a smart-TV operating-system provider could mean users who get streaming-service gift cards could sign up on the Roku platform, driving revenue to Roku. Plus, if streaming services want to steer potential gift givers to their own offerings, such firms might look to advertise on Roku’s platform, they said.","news_type":1,"symbols_score_info":{"ROKU":0.9}},"isVote":1,"tweetType":1,"viewCount":515,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600664647,"gmtCreate":1638148320752,"gmtModify":1638148320817,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/600664647","repostId":"1169118930","repostType":4,"repost":{"id":"1169118930","kind":"news","pubTimestamp":1638146156,"share":"https://www.laohu8.com/m/news/1169118930?lang=&edition=full","pubTime":"2021-11-29 08:35","market":"us","language":"en","title":"IBM Cast Off Kyndryl. Here’s What Investors Should Do With the Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1169118930","media":"Marketwatch","summary":"A key part of IBM’s turnaround story was written in early November: packaging the company’s low-marg","content":"<p>A key part of IBM’s turnaround story was written in early November: packaging the company’s low-margin, negative-growth information-technology services business, giving it a cool-sounding name, and getting it off the income statement.</p>\n<p>That’s how Kyndryl Holdings (ticker: KD) was born. The new/old company is a leading player in the IT managed services business, running data centers and other IT operations for more than 4,000 customers.</p>\n<p>Kyndryl has 90,000 employees and dominates the sector. The company had $19.1 billion in revenue, on a pro forma basis, in 2020, about twice as much as rival DXC Technology (DXC), according to Kyndryl’s spinoff documents. It has an even bigger edge on peers such as Atos (ATO.France), HCL Technologies (532281.India), Tata Consultancy Services (532540.India), and Cognizant (CTSH).</p>\n<p>IBM stockholders got one share of Kyndryl for every five IBM shares held.</p>\n<p>Kyndryl CEO Martin Schroeter recently told Barron’s that he views the company as a “$19 billion start-up,” which is reconfiguring its business for a world in which more and more IT workloads are shifting to the cloud and away from data centers. He says the spinoff will let the company reposition itself for growth, using mergers and acquisitions and internal development to adjust its business mix.</p>\n<p>But Kyndryl is having trouble finding its own independent investor base. In late October, the stock traded above $40 on a “when issued” basis. Kyndryl opened for trading on Nov. 4 at $28.41, and has continued to fall from there.</p>\n<p>At a recent price of $17.30, Kyndryl has a market cap of just $3.9 billion. With $1.2 billion in net debt, its enterprise value comes to $5.1 billion. That gives the company an enterprise value to sales multiple of less than 0.3. There are just four companies in the S&amp;P 500 index with a multiple lower than that. DXC trades for about 0.7 times projected revenue for its March 2022 fiscal year.</p>\n<p>But there are reasons that IBM investors—and others—are shunning the spun-off stock. For one thing, IBM has been attractive to investors in part for its 5.6% dividend yield, the highest of any company in the Dow Jones Industrial Average, and one of the highest in the S&amp;P 500. Anyone who owns IBM for the yield isn’t interested in Kyndryl stock.</p>\n<p>Another issue: Kyndryl doesn’t expect to show growth before 2025. The company projects 2021 revenue of $18.5 billion to $18.7 billion; at the midpoint, that’s a 2.6% decline from 2020’s level. Kyndryl sees adjusted earnings before interest, taxes, depreciation, and amortization, or Ebitda, of $2.8 billion to $2.9 billion.</p>\n<p>For investors, there’s little incentive to own a shrinking IT services company without a dividend yield. Short of a private-equity buyout—with the idea of revamping the company out of sight of the public markets—there are few near-term catalysts for Kyndryl stock.</p>\n<p>IBM shareholders have plenty of potential upside from that company’s core business. They don’t need to hold Kyndryl stock.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IBM Cast Off Kyndryl. Here’s What Investors Should Do With the Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIBM Cast Off Kyndryl. Here’s What Investors Should Do With the Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-29 08:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/ibm-kyndryl-stock-what-to-do-51637798963?mod=newsviewer_click_seemore><strong>Marketwatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A key part of IBM’s turnaround story was written in early November: packaging the company’s low-margin, negative-growth information-technology services business, giving it a cool-sounding name, and ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/ibm-kyndryl-stock-what-to-do-51637798963?mod=newsviewer_click_seemore\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IBM":"IBM","KD":"Kyndryl"},"source_url":"https://www.marketwatch.com/articles/ibm-kyndryl-stock-what-to-do-51637798963?mod=newsviewer_click_seemore","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1169118930","content_text":"A key part of IBM’s turnaround story was written in early November: packaging the company’s low-margin, negative-growth information-technology services business, giving it a cool-sounding name, and getting it off the income statement.\nThat’s how Kyndryl Holdings (ticker: KD) was born. The new/old company is a leading player in the IT managed services business, running data centers and other IT operations for more than 4,000 customers.\nKyndryl has 90,000 employees and dominates the sector. The company had $19.1 billion in revenue, on a pro forma basis, in 2020, about twice as much as rival DXC Technology (DXC), according to Kyndryl’s spinoff documents. It has an even bigger edge on peers such as Atos (ATO.France), HCL Technologies (532281.India), Tata Consultancy Services (532540.India), and Cognizant (CTSH).\nIBM stockholders got one share of Kyndryl for every five IBM shares held.\nKyndryl CEO Martin Schroeter recently told Barron’s that he views the company as a “$19 billion start-up,” which is reconfiguring its business for a world in which more and more IT workloads are shifting to the cloud and away from data centers. He says the spinoff will let the company reposition itself for growth, using mergers and acquisitions and internal development to adjust its business mix.\nBut Kyndryl is having trouble finding its own independent investor base. In late October, the stock traded above $40 on a “when issued” basis. Kyndryl opened for trading on Nov. 4 at $28.41, and has continued to fall from there.\nAt a recent price of $17.30, Kyndryl has a market cap of just $3.9 billion. With $1.2 billion in net debt, its enterprise value comes to $5.1 billion. That gives the company an enterprise value to sales multiple of less than 0.3. There are just four companies in the S&P 500 index with a multiple lower than that. DXC trades for about 0.7 times projected revenue for its March 2022 fiscal year.\nBut there are reasons that IBM investors—and others—are shunning the spun-off stock. For one thing, IBM has been attractive to investors in part for its 5.6% dividend yield, the highest of any company in the Dow Jones Industrial Average, and one of the highest in the S&P 500. Anyone who owns IBM for the yield isn’t interested in Kyndryl stock.\nAnother issue: Kyndryl doesn’t expect to show growth before 2025. The company projects 2021 revenue of $18.5 billion to $18.7 billion; at the midpoint, that’s a 2.6% decline from 2020’s level. Kyndryl sees adjusted earnings before interest, taxes, depreciation, and amortization, or Ebitda, of $2.8 billion to $2.9 billion.\nFor investors, there’s little incentive to own a shrinking IT services company without a dividend yield. Short of a private-equity buyout—with the idea of revamping the company out of sight of the public markets—there are few near-term catalysts for Kyndryl stock.\nIBM shareholders have plenty of potential upside from that company’s core business. They don’t need to hold Kyndryl stock.","news_type":1,"symbols_score_info":{"IBM":0.9,"KD":0.9}},"isVote":1,"tweetType":1,"viewCount":580,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600994356,"gmtCreate":1638028692653,"gmtModify":1638028692758,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/600994356","repostId":"1187736093","repostType":4,"repost":{"id":"1187736093","kind":"news","pubTimestamp":1637973799,"share":"https://www.laohu8.com/m/news/1187736093?lang=&edition=full","pubTime":"2021-11-27 08:43","market":"us","language":"en","title":"Amazon faces Black Friday strikes by workers across Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=1187736093","media":"CNN","summary":"Amazon(AMZN)is facing strikes by warehouse workers and delivery drivers across Europe as its busiest","content":"<p>Amazon(AMZN)is facing strikes by warehouse workers and delivery drivers across Europe as its busiest weekend of the year begins.</p>\n<p>Labor unions in Germany, Italy and France are calling for the company to pay its workers fairly and respect their right to join unions. The strikes have been called to coincide with Amazon's annual Black Friday event, which kicks off a four-day shopping bonanza that culminates in Cyber Monday.</p>\n<p>The action is part of a wider global protest organized by a group called Make Amazon Pay. The coalition of unions, environmentalists and tax campaigners has called for protests in22 countries around the world, including the United States, Canada, Brazil, and the United Kingdom.</p>\n<p>The international coalition is also demanding that Amazon \"pays its fair share of taxes and commits to real environmental sustainability.\"</p>\n<p>An Amazon spokesperson said that the groups represented a variety of interests, and while the company was \"not perfect in any area\" it was taking its role and impact seriously.\"</p>\n<p>We are inventing and investing significantly in all these areas, playing a significant role in addressing climate change with the Climate Pledge commitment to be net zero carbon by 2040, continuing to offer competitive wages and great benefits, and inventing new ways to keep our employees safe and healthy in our operations network, to name just a few,\" the spokesperson added.</p>\n<p>Some of its workers are not convinced.</p>\n<p>Germany's giant Verdi union organized a strike of warehouse workers to coincide with the launch in Berlin of \"Amazon Workers against Surveillance,\" a group protesting the company's \"use of apps, hand scanners, browser tools and cameras to surveil its workforce 24/7.\"</p>\n<p>\"Working almost anywhere at Amazon is stressful and hazardous to one's health,\" the group said in a statement on its website.</p>\n<p>In Italy, workers are planning to blockade warehouses and trucks at all Amazon centers across the country, and thousands of drivers are set to strike on Friday.</p>\n<p>Warehouse workers are also striking in France, including at a logistics center in Lille, in support of demands for wage increases and bonuses, and an end to compulsory overtime.</p>\n<p>They told CNN that Amazon has asked employees to work on all four Saturdays during December, in addition to their usual hours. For this overtime, they would get a bonus of €120 euros ($136) subject to certain conditions, the workers said.</p>\n<p>It's not clear how disruptive the strikes will be for Amazon, but this holiday shopping season is proving tough for retailers trying to satisfy strongconsumer demandin the face of supply chain disruptions, and shortages of workers and some goods.</p>\n<p>Make Amazon Pay was launched a year ago after 50 organizations held strikes and protests in 16 countries around the world, the coalition said.</p>\n<p>\"Today's actions show the scale of resistance to Amazon's exploitation at every link in its chain of abuse,\" said Casper Gelderblom, a coordinator of the group.</p>\n<p>\"Workers throughout the supply chain are demanding what's rightfully theirs when even Jeff Bezos admits their labor paid for his recent joy ride to space,\" he added.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon faces Black Friday strikes by workers across Europe</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon faces Black Friday strikes by workers across Europe\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-27 08:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://edition.cnn.com/2021/11/26/tech/amazon-workers-strike-shopping-holiday/index.html><strong>CNN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amazon(AMZN)is facing strikes by warehouse workers and delivery drivers across Europe as its busiest weekend of the year begins.\nLabor unions in Germany, Italy and France are calling for the company ...</p>\n\n<a href=\"https://edition.cnn.com/2021/11/26/tech/amazon-workers-strike-shopping-holiday/index.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊"},"source_url":"https://edition.cnn.com/2021/11/26/tech/amazon-workers-strike-shopping-holiday/index.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1187736093","content_text":"Amazon(AMZN)is facing strikes by warehouse workers and delivery drivers across Europe as its busiest weekend of the year begins.\nLabor unions in Germany, Italy and France are calling for the company to pay its workers fairly and respect their right to join unions. The strikes have been called to coincide with Amazon's annual Black Friday event, which kicks off a four-day shopping bonanza that culminates in Cyber Monday.\nThe action is part of a wider global protest organized by a group called Make Amazon Pay. The coalition of unions, environmentalists and tax campaigners has called for protests in22 countries around the world, including the United States, Canada, Brazil, and the United Kingdom.\nThe international coalition is also demanding that Amazon \"pays its fair share of taxes and commits to real environmental sustainability.\"\nAn Amazon spokesperson said that the groups represented a variety of interests, and while the company was \"not perfect in any area\" it was taking its role and impact seriously.\"\nWe are inventing and investing significantly in all these areas, playing a significant role in addressing climate change with the Climate Pledge commitment to be net zero carbon by 2040, continuing to offer competitive wages and great benefits, and inventing new ways to keep our employees safe and healthy in our operations network, to name just a few,\" the spokesperson added.\nSome of its workers are not convinced.\nGermany's giant Verdi union organized a strike of warehouse workers to coincide with the launch in Berlin of \"Amazon Workers against Surveillance,\" a group protesting the company's \"use of apps, hand scanners, browser tools and cameras to surveil its workforce 24/7.\"\n\"Working almost anywhere at Amazon is stressful and hazardous to one's health,\" the group said in a statement on its website.\nIn Italy, workers are planning to blockade warehouses and trucks at all Amazon centers across the country, and thousands of drivers are set to strike on Friday.\nWarehouse workers are also striking in France, including at a logistics center in Lille, in support of demands for wage increases and bonuses, and an end to compulsory overtime.\nThey told CNN that Amazon has asked employees to work on all four Saturdays during December, in addition to their usual hours. For this overtime, they would get a bonus of €120 euros ($136) subject to certain conditions, the workers said.\nIt's not clear how disruptive the strikes will be for Amazon, but this holiday shopping season is proving tough for retailers trying to satisfy strongconsumer demandin the face of supply chain disruptions, and shortages of workers and some goods.\nMake Amazon Pay was launched a year ago after 50 organizations held strikes and protests in 16 countries around the world, the coalition said.\n\"Today's actions show the scale of resistance to Amazon's exploitation at every link in its chain of abuse,\" said Casper Gelderblom, a coordinator of the group.\n\"Workers throughout the supply chain are demanding what's rightfully theirs when even Jeff Bezos admits their labor paid for his recent joy ride to space,\" he added.","news_type":1,"symbols_score_info":{"AMZN":0.9}},"isVote":1,"tweetType":1,"viewCount":533,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877046602,"gmtCreate":1637850335798,"gmtModify":1637850386437,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877046602","repostId":"1143924299","repostType":4,"repost":{"id":"1143924299","kind":"news","pubTimestamp":1637846658,"share":"https://www.laohu8.com/m/news/1143924299?lang=&edition=full","pubTime":"2021-11-25 21:24","market":"us","language":"en","title":"What Inflation? Small Investors Keep Piling Into Flashy Growth Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=1143924299","media":"WSJ","summary":"Conventional Wall Street wisdom says inflation is bad for growth and technology stocks. Many small i","content":"<p>Conventional Wall Street wisdom says inflation is bad for growth and technology stocks. Many small investors don’t care.</p>\n<p>Individual investors continue to stampede into shares of growth companies, the types of buzzy stocks that have enjoyed explosive price gains this year. Advanced Micro Devices Inc.,&nbsp;Nvidia Corp. and Apple Inc. are the three stocks most purchased this month by individual investors, according to VandaTrack, a Vanda Research flow tracker that measures net purchases.</p>\n<p>Growth stocks are typically companies—often tech firms—that are expected to deliver faster-than-average profit growth in the future. They tend to flourish in a low-rate environment, including over the past year and a half. Investors are typically willing to pay higher prices for such companies when they don’t see many alternatives for making sizable profits.</p>\n<p>For example, 18 of the stocks that are most favored by individual investors, including the chip makers AMD and Nvidia, trade on average at nearly 13 times their trailing 12-month sales, according to an analysis by Dow Jones Market Data. Stocks in the S&amp;P 500 trade at an average of three times their sales.</p>\n<p>But mounting inflation can be troublesome for growth stocks. That is because inflation brings the prospect of higher interest rates and higher bond yields, making the future cash flows of growth stocks less attractive. Traders, in turn, typically shuffle their portfolios to include other investments that stand to benefit from rising rates.</p>\n<p>A government report this month showed that the consumer-price index jumped 6.2% in October from a year earlier, climbing atthe fastest pace in three decades. Fund-flow tracker EPFR, whose data captures mostly institutional investor behavior, estimates that investors responded by yanking more than $2 billion out of U.S. tech-focused mutual and exchange-traded funds in the two weeks ended Nov. 17. That marks the worst stretch since a two-week period ended in early January 2019.</p>\n<p>At the same time, institutional investors are pumping money into more value-oriented sectors, such as consumer goods, healthcare and utilities, EPFR data show. Those industries tend to trade at lower valuations and tend to be more defensive moves for investors during times of heightened uncertainty.</p>\n<p>Greg Hahn, chief investment officer of Indianapolis-based Winthrop Capital Management, said his team has been paring back exposure to large-cap technology stocks.</p>\n<p>“We’re shifting out of growth,” Mr. Hahn said. Instead, the firm is focused on finding quality companies that have reasonable valuations and strong balance sheets—ones that are “sustainable in a potentially rough next market cycle,” he said.</p>\n<p>Recently, Mr. Hahn said, he has added exposure to a company that manufactures engines and generators and a pharmaceutical company that produces medicines and other products for animals.</p>\n<p>To be sure, U.S. stocks are still hovering near records, bond yields remain historically low and&nbsp;an earlier rally in gold prices&nbsp;has subsided. That suggests that inflation fears haven’t yet spurred many professional investors to entirely upend their playbooks. Some 61% of fund managers surveyed this month believe inflation is transitory, according to Bank of America Global Research.</p>\n<p>Still, the recent divergence in strategy between professional and individual investors is the latest example of&nbsp;the unusual dynamics that have played out in financial markets&nbsp;this year. Repeatedly, small investors&nbsp;have upended longstanding trading strategies&nbsp;by sending stocks such asGameStopCorp.andHertz Global HoldingsInc.HTZ11.06%soaring, with little regard for the companies’ underlying value. Some rely on classic momentum investing—a strategy of buying assets simply because they are rising.</p>\n<p>It isn’t uncommon for stocks favored by individual investors to be volatile. But those stocks can pay off too: AMD and Nvidia are each up 28% or more month-to-date, while Apple has climbed 8.1%. That compares with a 2.1% rise for the S&amp;P 500.</p>\n<p>“The lesson we’ve learned over the past 12 to 18 months…is that IPOs, fiscal stimulus and other micro [events] are much bigger drivers for retail investor behavior” than inflation readings, said Viraj Patel, global macro strategist at Vanda Research. “We’ve never woken up the day after the CPI and seen huge selling from retail investors.”</p>\n<p>Matt Delao, a 28-year-old individual investor from California, said he has followed data on inflation and supply-chain snarls this year. But he said his trading strategy has focused mostly on screening for stocks that appear priced for a significant move. Recently, he has traded options for AMD and bitcoin-mining companyRiot Blockchain&nbsp;Inc.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Inflation? Small Investors Keep Piling Into Flashy Growth Stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Inflation? Small Investors Keep Piling Into Flashy Growth Stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-25 21:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/what-inflation-small-investors-keep-piling-into-flashy-growth-stocks-11637836200?siteid=yhoof2><strong>WSJ</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Conventional Wall Street wisdom says inflation is bad for growth and technology stocks. Many small investors don’t care.\nIndividual investors continue to stampede into shares of growth companies, the ...</p>\n\n<a href=\"https://www.wsj.com/articles/what-inflation-small-investors-keep-piling-into-flashy-growth-stocks-11637836200?siteid=yhoof2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVDA":"英伟达","AAPL":"苹果","AMD":"美国超微公司"},"source_url":"https://www.wsj.com/articles/what-inflation-small-investors-keep-piling-into-flashy-growth-stocks-11637836200?siteid=yhoof2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143924299","content_text":"Conventional Wall Street wisdom says inflation is bad for growth and technology stocks. Many small investors don’t care.\nIndividual investors continue to stampede into shares of growth companies, the types of buzzy stocks that have enjoyed explosive price gains this year. Advanced Micro Devices Inc., Nvidia Corp. and Apple Inc. are the three stocks most purchased this month by individual investors, according to VandaTrack, a Vanda Research flow tracker that measures net purchases.\nGrowth stocks are typically companies—often tech firms—that are expected to deliver faster-than-average profit growth in the future. They tend to flourish in a low-rate environment, including over the past year and a half. Investors are typically willing to pay higher prices for such companies when they don’t see many alternatives for making sizable profits.\nFor example, 18 of the stocks that are most favored by individual investors, including the chip makers AMD and Nvidia, trade on average at nearly 13 times their trailing 12-month sales, according to an analysis by Dow Jones Market Data. Stocks in the S&P 500 trade at an average of three times their sales.\nBut mounting inflation can be troublesome for growth stocks. That is because inflation brings the prospect of higher interest rates and higher bond yields, making the future cash flows of growth stocks less attractive. Traders, in turn, typically shuffle their portfolios to include other investments that stand to benefit from rising rates.\nA government report this month showed that the consumer-price index jumped 6.2% in October from a year earlier, climbing atthe fastest pace in three decades. Fund-flow tracker EPFR, whose data captures mostly institutional investor behavior, estimates that investors responded by yanking more than $2 billion out of U.S. tech-focused mutual and exchange-traded funds in the two weeks ended Nov. 17. That marks the worst stretch since a two-week period ended in early January 2019.\nAt the same time, institutional investors are pumping money into more value-oriented sectors, such as consumer goods, healthcare and utilities, EPFR data show. Those industries tend to trade at lower valuations and tend to be more defensive moves for investors during times of heightened uncertainty.\nGreg Hahn, chief investment officer of Indianapolis-based Winthrop Capital Management, said his team has been paring back exposure to large-cap technology stocks.\n“We’re shifting out of growth,” Mr. Hahn said. Instead, the firm is focused on finding quality companies that have reasonable valuations and strong balance sheets—ones that are “sustainable in a potentially rough next market cycle,” he said.\nRecently, Mr. Hahn said, he has added exposure to a company that manufactures engines and generators and a pharmaceutical company that produces medicines and other products for animals.\nTo be sure, U.S. stocks are still hovering near records, bond yields remain historically low and an earlier rally in gold prices has subsided. That suggests that inflation fears haven’t yet spurred many professional investors to entirely upend their playbooks. Some 61% of fund managers surveyed this month believe inflation is transitory, according to Bank of America Global Research.\nStill, the recent divergence in strategy between professional and individual investors is the latest example of the unusual dynamics that have played out in financial markets this year. Repeatedly, small investors have upended longstanding trading strategies by sending stocks such asGameStopCorp.andHertz Global HoldingsInc.HTZ11.06%soaring, with little regard for the companies’ underlying value. Some rely on classic momentum investing—a strategy of buying assets simply because they are rising.\nIt isn’t uncommon for stocks favored by individual investors to be volatile. But those stocks can pay off too: AMD and Nvidia are each up 28% or more month-to-date, while Apple has climbed 8.1%. That compares with a 2.1% rise for the S&P 500.\n“The lesson we’ve learned over the past 12 to 18 months…is that IPOs, fiscal stimulus and other micro [events] are much bigger drivers for retail investor behavior” than inflation readings, said Viraj Patel, global macro strategist at Vanda Research. “We’ve never woken up the day after the CPI and seen huge selling from retail investors.”\nMatt Delao, a 28-year-old individual investor from California, said he has followed data on inflation and supply-chain snarls this year. But he said his trading strategy has focused mostly on screening for stocks that appear priced for a significant move. Recently, he has traded options for AMD and bitcoin-mining companyRiot Blockchain Inc.","news_type":1,"symbols_score_info":{"AAPL":0.9,"AMD":0.9,"NVDA":0.9}},"isVote":1,"tweetType":1,"viewCount":704,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874112818,"gmtCreate":1637742704688,"gmtModify":1637742704760,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/874112818","repostId":"1127565646","repostType":4,"isVote":1,"tweetType":1,"viewCount":727,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":897299671,"gmtCreate":1628919244593,"gmtModify":1631893764054,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/897299671","repostId":"2159321505","repostType":4,"repost":{"id":"2159321505","kind":"highlight","pubTimestamp":1628911811,"share":"https://www.laohu8.com/m/news/2159321505?lang=&edition=full","pubTime":"2021-08-14 11:30","market":"us","language":"en","title":"Tesla seeks to reduce board members’ terms, make other changes in October shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2159321505","media":"MarketWatch","summary":"Board members would serve for two years rather than three\nTesla CEO Elon Musk in Germany last year. ","content":"<p>Board members would serve for two years rather than three</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/abc701f141f0c0044cabe912e510fe2e\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Tesla CEO Elon Musk in Germany last year. MAJA HITIJ/GETTY IMAGES</span></p>\n<p>Tesla Inc. set its shareholder meeting for Oct. 7 at the Fremont, Calif., factory, with a call for reducing its directors’ terms among the proposals the electric-car maker will bring to the table, the company said in filing late Friday.</p>\n<p>One of the proposals calls for each director’s term to be reduced from three years to two years. Tesla’s&nbsp;board currently has nine members who are divided into three classes in staggered three-year terms.</p>\n<p>If the proposal is approved, however, the board will be divided into two classes with staggered two-year terms, with directors distributed as equally between the classes as possible, Tesla said in the&nbsp;filing.</p>\n<p>The board would be reduced to eight members, since Antonio Gracias, a venture capitalist who has served on the Tesla board since 2007, said in 2019 he’d not be seeking reelection when his term ends this year.</p>\n<p>Tesla’s board nominated current board members James Murdoch, the youngest son of News Corp&nbsp;founder Rupert Murdoch, and Kimbal Musk, Chief Executive Elon Musk’s brother, for re-election as class II directors, with terms expiring in 2024. If the term reduction is approved, then their terms would end in 2023, the company said.</p>\n<p>Tesla’s curtailing board member terms was a response to a shareholder proposal calling to elect each board member for one year.</p>\n<p>The two-year term, however, “strikes a suitable balance to the long-term interests of and nearer-term accountability to our stockholders at this time,” Tesla said.</p>\n<p>Tesla shares were flat in after-hours trading after ending the regular trading day down 0.7%. The stock has gained 1.6% this year, compared with gains of around 19% for the S&amp;P 500 index.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla seeks to reduce board members’ terms, make other changes in October shareholder meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla seeks to reduce board members’ terms, make other changes in October shareholder meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-14 11:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/tesla-seeks-to-reduce-board-terms-in-october-shareholder-meeting-11628888340?mod=newsviewer_click><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Board members would serve for two years rather than three\nTesla CEO Elon Musk in Germany last year. MAJA HITIJ/GETTY IMAGES\nTesla Inc. set its shareholder meeting for Oct. 7 at the Fremont, Calif., ...</p>\n\n<a href=\"https://www.marketwatch.com/story/tesla-seeks-to-reduce-board-terms-in-october-shareholder-meeting-11628888340?mod=newsviewer_click\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.marketwatch.com/story/tesla-seeks-to-reduce-board-terms-in-october-shareholder-meeting-11628888340?mod=newsviewer_click","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2159321505","content_text":"Board members would serve for two years rather than three\nTesla CEO Elon Musk in Germany last year. MAJA HITIJ/GETTY IMAGES\nTesla Inc. set its shareholder meeting for Oct. 7 at the Fremont, Calif., factory, with a call for reducing its directors’ terms among the proposals the electric-car maker will bring to the table, the company said in filing late Friday.\nOne of the proposals calls for each director’s term to be reduced from three years to two years. Tesla’s board currently has nine members who are divided into three classes in staggered three-year terms.\nIf the proposal is approved, however, the board will be divided into two classes with staggered two-year terms, with directors distributed as equally between the classes as possible, Tesla said in the filing.\nThe board would be reduced to eight members, since Antonio Gracias, a venture capitalist who has served on the Tesla board since 2007, said in 2019 he’d not be seeking reelection when his term ends this year.\nTesla’s board nominated current board members James Murdoch, the youngest son of News Corp founder Rupert Murdoch, and Kimbal Musk, Chief Executive Elon Musk’s brother, for re-election as class II directors, with terms expiring in 2024. If the term reduction is approved, then their terms would end in 2023, the company said.\nTesla’s curtailing board member terms was a response to a shareholder proposal calling to elect each board member for one year.\nThe two-year term, however, “strikes a suitable balance to the long-term interests of and nearer-term accountability to our stockholders at this time,” Tesla said.\nTesla shares were flat in after-hours trading after ending the regular trading day down 0.7%. The stock has gained 1.6% this year, compared with gains of around 19% for the S&P 500 index.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":316,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":808670110,"gmtCreate":1627578379830,"gmtModify":1633758103132,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/808670110","repostId":"1165497040","repostType":4,"isVote":1,"tweetType":1,"viewCount":317,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":604301439,"gmtCreate":1639325093032,"gmtModify":1639325093141,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/604301439","repostId":"2190719536","repostType":4,"isVote":1,"tweetType":1,"viewCount":2028,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":820897525,"gmtCreate":1633365842564,"gmtModify":1633365842753,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/820897525","repostId":"2172996701","repostType":4,"isVote":1,"tweetType":1,"viewCount":451,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":899357758,"gmtCreate":1628163799674,"gmtModify":1633753041855,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/899357758","repostId":"1121665544","repostType":4,"isVote":1,"tweetType":1,"viewCount":219,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":693069194,"gmtCreate":1639930012033,"gmtModify":1639930012195,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/693069194","repostId":"1122414343","repostType":4,"repost":{"id":"1122414343","kind":"news","pubTimestamp":1639884070,"share":"https://www.laohu8.com/m/news/1122414343?lang=&edition=full","pubTime":"2021-12-19 11:21","market":"us","language":"en","title":"Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade","url":"https://stock-news.laohu8.com/highlight/detail?id=1122414343","media":"Seeking Alpha","summary":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5","content":"<p>The healthcare stocks in the S&amp;P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&amp;A prospects. <a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.</p>\n<p>Among stocks with more than $2B market capitalization and 100K average daily volume over the past week, <a href=\"https://laohu8.com/S/ARNA\">Arena Pharmaceuticals </a> dominated with a ~83.8% rise after <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. <a href=\"https://laohu8.com/S/CERN\">Cerner </a> also joined the M&amp;A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from <a href=\"https://laohu8.com/S/ORCL\">Oracle </a> for the electronic-medical-records company.</p>\n<p>Vaccine developer, <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.</p>\n<p><a href=\"https://laohu8.com/S/BHVN\">Biohaven Pharmaceutical </a> posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, <a href=\"https://laohu8.com/S/ROIV\">Roivant Sciences </a> added ~22.6%.</p>\n<p>Notable gainer: <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the <a href=\"https://laohu8.com/S/NWY\">New York</a>-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.</p>\n<p>Among worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.</p>\n<p>Last week’s best performer, <a href=\"https://laohu8.com/S/BHG\">Bright Health Group</a>, crashed ~13.1%, hurt by the sole Sell rating issued by <a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a> even as the investment bank kicked off its coverage on managed care with largely positive views.</p>\n<p>Allogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic <a href=\"https://laohu8.com/S/00699\">CAR</a> T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax, Vir among healthcare gainers, Pfizer posts best rally in a decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-19 11:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the ...</p>\n\n<a href=\"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4534":"瑞士信贷持仓","ORCL":"甲骨文","BK4533":"AQR资本管理(全球第二大对冲基金)","ARNA":"阿里那","CERN":"美国塞纳","BK4007":"制药","PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122414343","content_text":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.\nAmong stocks with more than $2B market capitalization and 100K average daily volume over the past week, Arena Pharmaceuticals  dominated with a ~83.8% rise after Pfizer  agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. Cerner  also joined the M&A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from Oracle  for the electronic-medical-records company.\nVaccine developer, Novavax  jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.\nBiohaven Pharmaceutical  posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, Roivant Sciences  added ~22.6%.\nNotable gainer: Pfizer (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the New York-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.\nAmong worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.\nLast week’s best performer, Bright Health Group, crashed ~13.1%, hurt by the sole Sell rating issued by Goldman Sachs even as the investment bank kicked off its coverage on managed care with largely positive views.\nAllogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic CAR T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.","news_type":1,"symbols_score_info":{"ARNA":0.9,"CERN":0.9,"ORCL":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1820,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690059971,"gmtCreate":1639615627130,"gmtModify":1639615627236,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/690059971","repostId":"1172070133","repostType":4,"repost":{"id":"1172070133","kind":"news","pubTimestamp":1639621250,"share":"https://www.laohu8.com/m/news/1172070133?lang=&edition=full","pubTime":"2021-12-16 10:20","market":"us","language":"en","title":"All the doves at the Fed have become hawks","url":"https://stock-news.laohu8.com/highlight/detail?id=1172070133","media":"MarketWatch","summary":"The U.S. central bank charts a completely new course to attack inflation rather than continue to wai","content":"<p>The U.S. central bank charts a completely new course to attack inflation rather than continue to wait it out</p>\n<p><img src=\"https://static.tigerbbs.com/ba1b24817095f66e1cbf69b3dd7a4ad8\" tg-width=\"700\" tg-height=\"399\" referrerpolicy=\"no-referrer\"></p>\n<p>The big news from the Federal Reserve’s meeting Wednesday wasn’t that it’ll stop buying bonds to stimulate the economy&nbsp;or that it’s now signaling three increases in its benchmark lending rate in 2022. Those short-term policy decisions had been well-telegraphed by Fed officials over the past month.</p>\n<p>No, the big surprise is that the gargantuan, change-averse Fed has turned 180 degrees in its view of inflation.</p>\n<p>The Fed’s statement&nbsp;Wednesday and the accompanying materials show that the doves — the policy makers who generally believe that the risk of inflation is overblown — have completely surrendered. Everyone’s a hawk now. There are no doves at the Fed anymore.</p>\n<p>Fed monetary-policy makers unanimously agree that fighting inflation is their No. 1 job. They may disagree on the tactics or the timing, but not on the strategy of vanquishing inflation soon. The Fed is on a war footing, and inflation is the enemy.</p>\n<p>For 30 years, the doves had been right: Inflation wasn’t the biggest threat to the economy; unemployment was. The doves fought an ultimately successful battle to force the Federal Reserve to consider the very real costs that unemployment forces upon society and the many individuals whom the economy was leaving behind.</p>\n<p>But now effects of the coronavirus pandemic have forced even the doves to accept that inflation is a bigger threat than unemployment. That’s a huge change in an institution that doesn’t like change.</p>\n<p>How do we know the doves have metamorphosed into hawks? Look at the dot plot, a chart the Fed releases every three months that shows the anonymous individual forecasts of each monetary-policy maker for the level of the federal funds rate at the ends of the next several years.</p>\n<p>Most analysts correctly focus on the median forecast for the coming year, but I’d like to redirect your attention briefly to the medium-term forecasts of the outliers, the most hawkish and dovish members of the Fed, to show how much the battlefield inside the Fed has changed since that horrendous consumer-price-index reading of Nov. 10. That report changed everything at the Fed.</p>\n<p><img src=\"https://static.tigerbbs.com/fc738ce106c9173e3b5b93bf435f87f7\" tg-width=\"700\" tg-height=\"644\" referrerpolicy=\"no-referrer\"></p>\n<p>In the latest forecasts released Wednesday, the most hawkish members raised their medium-term forecasts modestly from 1.63% to 2.13% at the end of 2023, and from 2.63% to 3.13% at the end of 2024. The five most hawkish members now think the Fed will have to push the fed funds rate above its assumed long-run equilibrium of 2.5%.</p>\n<p>But the doves completely tore up their previous forecasts. The five most dovish members were forecasting between zero and two rate hikes by the end of 2023, but now they expect four or five. By the end of 2024, they had been forecasting between two and four rate hikes; now they expect seven.</p>\n<p>Clearly, even the most dovish Fed officials now believe&nbsp;the fed funds rate must go up a lot to vanquish inflation. Before, they thought inflation would come down all by itself.</p>\n<p>This means that inflation no longer gets the benefit of the doubt. It’s been proven guilty, and even the doves will prosecute the war until victory is won. For the inflation doves at the Fed, Nov. 10, 2021, was bit of like Dec. 7, 1941: Time to go to war.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>All the doves at the Fed have become hawks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAll the doves at the Fed have become hawks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-16 10:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/all-the-doves-at-the-fed-have-become-hawks-11639613760?mod=mw_latestnews><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. central bank charts a completely new course to attack inflation rather than continue to wait it out\n\nThe big news from the Federal Reserve’s meeting Wednesday wasn’t that it’ll stop buying ...</p>\n\n<a href=\"https://www.marketwatch.com/story/all-the-doves-at-the-fed-have-become-hawks-11639613760?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://www.marketwatch.com/story/all-the-doves-at-the-fed-have-become-hawks-11639613760?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172070133","content_text":"The U.S. central bank charts a completely new course to attack inflation rather than continue to wait it out\n\nThe big news from the Federal Reserve’s meeting Wednesday wasn’t that it’ll stop buying bonds to stimulate the economy or that it’s now signaling three increases in its benchmark lending rate in 2022. Those short-term policy decisions had been well-telegraphed by Fed officials over the past month.\nNo, the big surprise is that the gargantuan, change-averse Fed has turned 180 degrees in its view of inflation.\nThe Fed’s statement Wednesday and the accompanying materials show that the doves — the policy makers who generally believe that the risk of inflation is overblown — have completely surrendered. Everyone’s a hawk now. There are no doves at the Fed anymore.\nFed monetary-policy makers unanimously agree that fighting inflation is their No. 1 job. They may disagree on the tactics or the timing, but not on the strategy of vanquishing inflation soon. The Fed is on a war footing, and inflation is the enemy.\nFor 30 years, the doves had been right: Inflation wasn’t the biggest threat to the economy; unemployment was. The doves fought an ultimately successful battle to force the Federal Reserve to consider the very real costs that unemployment forces upon society and the many individuals whom the economy was leaving behind.\nBut now effects of the coronavirus pandemic have forced even the doves to accept that inflation is a bigger threat than unemployment. That’s a huge change in an institution that doesn’t like change.\nHow do we know the doves have metamorphosed into hawks? Look at the dot plot, a chart the Fed releases every three months that shows the anonymous individual forecasts of each monetary-policy maker for the level of the federal funds rate at the ends of the next several years.\nMost analysts correctly focus on the median forecast for the coming year, but I’d like to redirect your attention briefly to the medium-term forecasts of the outliers, the most hawkish and dovish members of the Fed, to show how much the battlefield inside the Fed has changed since that horrendous consumer-price-index reading of Nov. 10. That report changed everything at the Fed.\n\nIn the latest forecasts released Wednesday, the most hawkish members raised their medium-term forecasts modestly from 1.63% to 2.13% at the end of 2023, and from 2.63% to 3.13% at the end of 2024. The five most hawkish members now think the Fed will have to push the fed funds rate above its assumed long-run equilibrium of 2.5%.\nBut the doves completely tore up their previous forecasts. The five most dovish members were forecasting between zero and two rate hikes by the end of 2023, but now they expect four or five. By the end of 2024, they had been forecasting between two and four rate hikes; now they expect seven.\nClearly, even the most dovish Fed officials now believe the fed funds rate must go up a lot to vanquish inflation. Before, they thought inflation would come down all by itself.\nThis means that inflation no longer gets the benefit of the doubt. It’s been proven guilty, and even the doves will prosecute the war until victory is won. For the inflation doves at the Fed, Nov. 10, 2021, was bit of like Dec. 7, 1941: Time to go to war.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":2311,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843633000,"gmtCreate":1635822183811,"gmtModify":1635822183877,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/843633000","repostId":"2180209403","repostType":4,"isVote":1,"tweetType":1,"viewCount":431,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":882126408,"gmtCreate":1631668390104,"gmtModify":1631888917475,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/882126408","repostId":"1148341685","repostType":4,"repost":{"id":"1148341685","kind":"news","pubTimestamp":1631660884,"share":"https://www.laohu8.com/m/news/1148341685?lang=&edition=full","pubTime":"2021-09-15 07:08","market":"us","language":"en","title":"U.S. stocks close lower on worries over recovery, corporate tax hikes","url":"https://stock-news.laohu8.com/highlight/detail?id=1148341685","media":"Reuters","summary":"NEW YORK (Reuters) - Wall Street lost ground on Tuesday as economic uncertainties and the increasing","content":"<p>NEW YORK (Reuters) - Wall Street lost ground on Tuesday as economic uncertainties and the increasing likelihood of a corporate tax rate hike dampened investor sentiment and prompted a broad sell-off despite signs of easing inflation.</p>\n<p>Optimism faded throughout the session, reversing an initial rally following the Labor Department’s consumer price index report. All three major U.S. stock indexes ended in negative territory in a reminder that September is a historically rough month for stocks.</p>\n<p>So far this month the S&amp;P 500 is down nearly 1.8% even as the benchmark index has gained over 18% since the beginning of the year.</p>\n<p>“There is a possibility that the market is simply ready to go through an overdue correction,” said Sam Stovall, chief investment strategist at CFRA Research in New York. “From a seasonality perspective, September tends to be the window dressing period for fund managers.”</p>\n<p>The advent of the highly contagious Delta COVID variant has driven an increase in bearish sentiment regarding the recovery from the global health crisis, and many now expect a substantial correction in stock markets by the end of the year.</p>\n<p>“We’re still in a corrective mode that people have been calling for months,” said Paul Nolte, portfolio manager at Kingsview Asset Management in Chicago. “Economic data points have been missing estimates, and that has coincided with the rise in the Delta variant.”</p>\n<p>The CPI report delivered a lower-than-consensus August reading, a deceleration that supports Federal Reserve Chairman Jerome Powell’s assertion that spiking inflation is transitory and calms market fears that the central bank will begin tightening monetary policy sooner than expected.</p>\n<p>U.S. Treasury yields dropped on the data, which pressured financial stocks, and investor favor pivoted back to growth at the expense of value. [US/]</p>\n<p>The long expected corporate tax hikes, to 26.5% from 21% if Democrats prevail, are coming nearer to fruition with U.S. President Joe Biden’s $3.5 trillion budget package inching closer to passage.</p>\n<p>The Dow Jones Industrial Average fell 292.06 points, or 0.84%, to 34,577.57; the S&amp;P 500 lost 25.68 points, or 0.57%, at 4,443.05; and the Nasdaq Composite dropped 67.82 points, or 0.45%, to 15,037.76.</p>\n<p>All 11 major sectors in the S&amp;P 500 ended the session red, with energy and financials suffering the largest percentage drops.</p>\n<p>Apple Inc unveiled its iPhone 13 and added new features to its iPad and Apple Watch gadgets in its biggest product launch event of the year as the company faces increased scrutiny in the courts over its business practices. Its shares closed down 1.0% and were the heaviest drag on the S&amp;P 500 and the Nasdaq.</p>\n<p>Intuit Inc gained 1.9% following the TurboTax maker’s announcement that it would acquire digital marketing company Mailchimp for $12 billion.</p>\n<p>CureVac slid 8.0% after the German biotechnology company canceled manufacturing deals for its experimental COVID-19 vaccine.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 2.25-to-1 ratio; on Nasdaq, a 2.40-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted two new 52-week highs and two new lows; the Nasdaq Composite recorded 50 new highs and 107 new lows.</p>\n<p>Volume on U.S. exchanges was 10.07 billion shares, compared with the 9.38 billion average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. stocks close lower on worries over recovery, corporate tax hikes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. stocks close lower on worries over recovery, corporate tax hikes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-15 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/usa-stocks/u-s-stocks-close-lower-on-worries-over-recovery-corporate-tax-hikes-idUSKBN2GA0W9><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK (Reuters) - Wall Street lost ground on Tuesday as economic uncertainties and the increasing likelihood of a corporate tax rate hike dampened investor sentiment and prompted a broad sell-off ...</p>\n\n<a href=\"https://www.reuters.com/article/usa-stocks/u-s-stocks-close-lower-on-worries-over-recovery-corporate-tax-hikes-idUSKBN2GA0W9\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"https://www.reuters.com/article/usa-stocks/u-s-stocks-close-lower-on-worries-over-recovery-corporate-tax-hikes-idUSKBN2GA0W9","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148341685","content_text":"NEW YORK (Reuters) - Wall Street lost ground on Tuesday as economic uncertainties and the increasing likelihood of a corporate tax rate hike dampened investor sentiment and prompted a broad sell-off despite signs of easing inflation.\nOptimism faded throughout the session, reversing an initial rally following the Labor Department’s consumer price index report. All three major U.S. stock indexes ended in negative territory in a reminder that September is a historically rough month for stocks.\nSo far this month the S&P 500 is down nearly 1.8% even as the benchmark index has gained over 18% since the beginning of the year.\n“There is a possibility that the market is simply ready to go through an overdue correction,” said Sam Stovall, chief investment strategist at CFRA Research in New York. “From a seasonality perspective, September tends to be the window dressing period for fund managers.”\nThe advent of the highly contagious Delta COVID variant has driven an increase in bearish sentiment regarding the recovery from the global health crisis, and many now expect a substantial correction in stock markets by the end of the year.\n“We’re still in a corrective mode that people have been calling for months,” said Paul Nolte, portfolio manager at Kingsview Asset Management in Chicago. “Economic data points have been missing estimates, and that has coincided with the rise in the Delta variant.”\nThe CPI report delivered a lower-than-consensus August reading, a deceleration that supports Federal Reserve Chairman Jerome Powell’s assertion that spiking inflation is transitory and calms market fears that the central bank will begin tightening monetary policy sooner than expected.\nU.S. Treasury yields dropped on the data, which pressured financial stocks, and investor favor pivoted back to growth at the expense of value. [US/]\nThe long expected corporate tax hikes, to 26.5% from 21% if Democrats prevail, are coming nearer to fruition with U.S. President Joe Biden’s $3.5 trillion budget package inching closer to passage.\nThe Dow Jones Industrial Average fell 292.06 points, or 0.84%, to 34,577.57; the S&P 500 lost 25.68 points, or 0.57%, at 4,443.05; and the Nasdaq Composite dropped 67.82 points, or 0.45%, to 15,037.76.\nAll 11 major sectors in the S&P 500 ended the session red, with energy and financials suffering the largest percentage drops.\nApple Inc unveiled its iPhone 13 and added new features to its iPad and Apple Watch gadgets in its biggest product launch event of the year as the company faces increased scrutiny in the courts over its business practices. Its shares closed down 1.0% and were the heaviest drag on the S&P 500 and the Nasdaq.\nIntuit Inc gained 1.9% following the TurboTax maker’s announcement that it would acquire digital marketing company Mailchimp for $12 billion.\nCureVac slid 8.0% after the German biotechnology company canceled manufacturing deals for its experimental COVID-19 vaccine.\nDeclining issues outnumbered advancing ones on the NYSE by a 2.25-to-1 ratio; on Nasdaq, a 2.40-to-1 ratio favored decliners.\nThe S&P 500 posted two new 52-week highs and two new lows; the Nasdaq Composite recorded 50 new highs and 107 new lows.\nVolume on U.S. exchanges was 10.07 billion shares, compared with the 9.38 billion average over the last 20 trading days.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":119,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":837334996,"gmtCreate":1629856604115,"gmtModify":1631891867720,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/837334996","repostId":"2162087564","repostType":4,"isVote":1,"tweetType":1,"viewCount":280,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":839919304,"gmtCreate":1629115220808,"gmtModify":1631893764041,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/839919304","repostId":"2159248377","repostType":4,"isVote":1,"tweetType":1,"viewCount":333,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":824932844,"gmtCreate":1634268041573,"gmtModify":1634274404573,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/824932844","repostId":"1129314610","repostType":4,"repost":{"id":"1129314610","kind":"news","pubTimestamp":1634253682,"share":"https://www.laohu8.com/m/news/1129314610?lang=&edition=full","pubTime":"2021-10-15 07:21","market":"us","language":"en","title":"S&P 500 surges, biggest daily percentage rise since March on earnings, data","url":"https://stock-news.laohu8.com/highlight/detail?id=1129314610","media":"Reuters","summary":"NEW YORK (Reuters) - The S&P 500 jumped on Thursday, its biggest daily percentage advance since earl","content":"<p>NEW YORK (Reuters) - The S&amp;P 500 jumped on Thursday, its biggest daily percentage advance since early March, as companies including <a href=\"https://laohu8.com/S/MS\">Morgan Stanley</a> and <a href=\"https://laohu8.com/S/UNH\">UnitedHealth</a> climbed following strong results, while data on the labor market and inflation soothed fears over the outlook for higher rates.</p>\n<p>The technology sector jumped 2.3%, giving the S&amp;P 500 its biggest boost, with shares of <a href=\"https://laohu8.com/S/MSFT\">Microsoft</a> Corp and <a href=\"https://laohu8.com/S/AAPL\">Apple</a> Inc rising.</p>\n<p>Shares of <a href=\"https://laohu8.com/S/C\">Citigroup</a>, $Bank of America Corp(BAC-N)$ and <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> also gained after they topped quarterly earnings estimates. The rebounding economy allowed them to release more cash they had set aside for pandemic losses, while sizzling deals, equity financing and trading added to profits. The S&amp;P bank index jumped 1.5%.</p>\n<p>Also, UnitedHealth Group Inc climbed 4.2% after the health insurer reported results and raised its full-year adjusted profit forecast on strength from its Optum unit that manages drug benefits.</p>\n<p>Adding to optimism, data showed the number of Americans filing new claims for unemployment benefits last week fell close to a 19-month low, and a separate report showed producer prices eased in September.</p>\n<p>Data from recent inflation reports suggested COVID-driven price increases may have peaked. Still, Federal Reserve policymakers remain divided over inflation and what to do about it.</p>\n<p>“Some of the things that worried the market in September, and even last week, as far as the inflation aspect and higher interest rates and the Delta variant, maybe have lessened,” said Alan Lancz, president, Alan B. Lancz &amp; Associates Inc., an investment advisory firm, based in Toledo, Ohio.</p>\n<p>“Not that it’s all over, but on a temporary scale at least, you can make a case for it trending in the right direction.”</p>\n<p>The Dow Jones Industrial Average rose 534.75 points, or 1.56%, to 34,912.56, the S&amp;P 500 gained 74.46 points, or 1.71%, to 4,438.26 and the <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> Composite added 251.8 points, or 1.73%, to 14,823.43.</p>\n<p>While the S&amp;P 500 registered its biggest daily percentage gain since March 5, the Nasdaq notched its biggest since May 20 and the Dow its biggest since July 20.</p>\n<p>Gains were broad-based, with all but <a href=\"https://laohu8.com/S/AONE.U\">one</a> S&amp;P 500 sector rising more than 1%.</p>\n<p>Shares of Moderna Inc ended up 3.2% after a panel of expert advisers to the U.S. Food and Drug Administration voted to recommend booster shots of its COVID-19 vaccine for Americans aged 65 and older and those at high risk of severe illness.</p>\n<p><a href=\"https://laohu8.com/S/WBA\">Walgreens Boots Alliance</a> Inc jumped 7.4% after the drugstore chain reported fourth-quarter revenue and adjusted profit above estimates and forecast growth of 11% to 13% in the long term.</p>\n<p>U.S. companies are expected to report strong profit growth for the third quarter, but investors have been keen to hear what they say about rising costs, labor shortages and supply problems.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 3.58-to-1 ratio; on Nasdaq, a 1.97-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 32 new 52-week highs and no new lows; the Nasdaq Composite recorded 82 new highs and 46 new lows.</p>\n<p>Volume on U.S. exchanges was 9.26 billion shares, compared with the 10.8 billion average for the full session over the last 20 trading days.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500 surges, biggest daily percentage rise since March on earnings, data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500 surges, biggest daily percentage rise since March on earnings, data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-15 07:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/usa-stocks/us-stocks-sp-500-surges-biggest-daily-percentage-rise-since-march-on-earnings-data-idUSL1N2RA2WC><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK (Reuters) - The S&P 500 jumped on Thursday, its biggest daily percentage advance since early March, as companies including Morgan Stanley and UnitedHealth climbed following strong results, ...</p>\n\n<a href=\"https://www.reuters.com/article/usa-stocks/us-stocks-sp-500-surges-biggest-daily-percentage-rise-since-march-on-earnings-data-idUSL1N2RA2WC\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF",".SPX":"S&P 500 Index","OEX":"标普100","SSO":"两倍做多标普500ETF",".DJI":"道琼斯","IVV":"标普500指数ETF","UPRO":"三倍做多标普500ETF","SPXU":"三倍做空标普500ETF","SH":"标普500反向ETF","SPY":"标普500ETF",".IXIC":"NASDAQ Composite","OEF":"标普100指数ETF-iShares","SDS":"两倍做空标普500ETF"},"source_url":"https://www.reuters.com/article/usa-stocks/us-stocks-sp-500-surges-biggest-daily-percentage-rise-since-march-on-earnings-data-idUSL1N2RA2WC","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129314610","content_text":"NEW YORK (Reuters) - The S&P 500 jumped on Thursday, its biggest daily percentage advance since early March, as companies including Morgan Stanley and UnitedHealth climbed following strong results, while data on the labor market and inflation soothed fears over the outlook for higher rates.\nThe technology sector jumped 2.3%, giving the S&P 500 its biggest boost, with shares of Microsoft Corp and Apple Inc rising.\nShares of Citigroup, $Bank of America Corp(BAC-N)$ and Morgan Stanley also gained after they topped quarterly earnings estimates. The rebounding economy allowed them to release more cash they had set aside for pandemic losses, while sizzling deals, equity financing and trading added to profits. The S&P bank index jumped 1.5%.\nAlso, UnitedHealth Group Inc climbed 4.2% after the health insurer reported results and raised its full-year adjusted profit forecast on strength from its Optum unit that manages drug benefits.\nAdding to optimism, data showed the number of Americans filing new claims for unemployment benefits last week fell close to a 19-month low, and a separate report showed producer prices eased in September.\nData from recent inflation reports suggested COVID-driven price increases may have peaked. Still, Federal Reserve policymakers remain divided over inflation and what to do about it.\n“Some of the things that worried the market in September, and even last week, as far as the inflation aspect and higher interest rates and the Delta variant, maybe have lessened,” said Alan Lancz, president, Alan B. Lancz & Associates Inc., an investment advisory firm, based in Toledo, Ohio.\n“Not that it’s all over, but on a temporary scale at least, you can make a case for it trending in the right direction.”\nThe Dow Jones Industrial Average rose 534.75 points, or 1.56%, to 34,912.56, the S&P 500 gained 74.46 points, or 1.71%, to 4,438.26 and the Nasdaq Composite added 251.8 points, or 1.73%, to 14,823.43.\nWhile the S&P 500 registered its biggest daily percentage gain since March 5, the Nasdaq notched its biggest since May 20 and the Dow its biggest since July 20.\nGains were broad-based, with all but one S&P 500 sector rising more than 1%.\nShares of Moderna Inc ended up 3.2% after a panel of expert advisers to the U.S. Food and Drug Administration voted to recommend booster shots of its COVID-19 vaccine for Americans aged 65 and older and those at high risk of severe illness.\nWalgreens Boots Alliance Inc jumped 7.4% after the drugstore chain reported fourth-quarter revenue and adjusted profit above estimates and forecast growth of 11% to 13% in the long term.\nU.S. companies are expected to report strong profit growth for the third quarter, but investors have been keen to hear what they say about rising costs, labor shortages and supply problems.\nAdvancing issues outnumbered declining ones on the NYSE by a 3.58-to-1 ratio; on Nasdaq, a 1.97-to-1 ratio favored advancers.\nThe S&P 500 posted 32 new 52-week highs and no new lows; the Nasdaq Composite recorded 82 new highs and 46 new lows.\nVolume on U.S. exchanges was 9.26 billion shares, compared with the 10.8 billion average for the full session over the last 20 trading days.","news_type":1,"symbols_score_info":{"161125":0.9,"513500":0.9,".DJI":0.9,".IXIC":0.9,".SPX":0.9,"ESmain":0.9,"IVV":0.9,"OEF":0.9,"OEX":0.9,"SDS":0.9,"SH":0.9,"SPXU":0.9,"SPY":0.9,"SSO":0.9,"UPRO":0.9}},"isVote":1,"tweetType":1,"viewCount":505,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":821403952,"gmtCreate":1633767019615,"gmtModify":1633767019615,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/821403952","repostId":"2174920514","repostType":4,"isVote":1,"tweetType":1,"viewCount":670,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":865713756,"gmtCreate":1633017656068,"gmtModify":1633017656227,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/865713756","repostId":"2171895899","repostType":4,"isVote":1,"tweetType":1,"viewCount":320,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":814092018,"gmtCreate":1630725026734,"gmtModify":1631888917595,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/814092018","repostId":"1186003479","repostType":4,"isVote":1,"tweetType":1,"viewCount":182,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":806901430,"gmtCreate":1627621300420,"gmtModify":1633757675608,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/806901430","repostId":"2155184148","repostType":4,"isVote":1,"tweetType":1,"viewCount":274,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":699270807,"gmtCreate":1639824405751,"gmtModify":1639824405859,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/699270807","repostId":"1189235922","repostType":4,"repost":{"id":"1189235922","kind":"news","pubTimestamp":1639809269,"share":"https://www.laohu8.com/m/news/1189235922?lang=&edition=full","pubTime":"2021-12-18 14:34","market":"us","language":"en","title":"DaVita authorizes additional $2B share repurchase","url":"https://stock-news.laohu8.com/highlight/detail?id=1189235922","media":"Seeking Alpha","summary":"DaVita  Board of Directors increased the authorization under the existing share repurchase program b","content":"<p><a href=\"https://laohu8.com/S/DVA\">DaVita </a> Board of Directors increased the authorization under the existing share repurchase program by $2B in additional repurchasing authority.</p>\n<p>The amount of shares authorized to be repurchased under the new authorization does not include the amount remaining under the company’s existing share repurchase program authorized on December 10, 2020 .</p>\n<p>Some bearish commentary and rating on the stock by SA contributor who writes: 'The company appears to be overvalued, and there are several challenges facing the company in the future.'</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DaVita authorizes additional $2B share repurchase</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDaVita authorizes additional $2B share repurchase\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-18 14:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3781473-davita-authorizes-additional-2b-share-repurchase><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DaVita  Board of Directors increased the authorization under the existing share repurchase program by $2B in additional repurchasing authority.\nThe amount of shares authorized to be repurchased under ...</p>\n\n<a href=\"https://seekingalpha.com/news/3781473-davita-authorizes-additional-2b-share-repurchase\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DVA":"达维塔保健"},"source_url":"https://seekingalpha.com/news/3781473-davita-authorizes-additional-2b-share-repurchase","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189235922","content_text":"DaVita  Board of Directors increased the authorization under the existing share repurchase program by $2B in additional repurchasing authority.\nThe amount of shares authorized to be repurchased under the new authorization does not include the amount remaining under the company’s existing share repurchase program authorized on December 10, 2020 .\nSome bearish commentary and rating on the stock by SA contributor who writes: 'The company appears to be overvalued, and there are several challenges facing the company in the future.'","news_type":1,"symbols_score_info":{"DVA":0.9}},"isVote":1,"tweetType":1,"viewCount":1616,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872026671,"gmtCreate":1637378019821,"gmtModify":1637378019993,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/872026671","repostId":"1111549440","repostType":4,"repost":{"id":"1111549440","kind":"news","pubTimestamp":1637372002,"share":"https://www.laohu8.com/m/news/1111549440?lang=&edition=full","pubTime":"2021-11-20 09:33","market":"us","language":"en","title":"Bristol Myers Stock Keeps Skidding on FDA Heart Drug Review","url":"https://stock-news.laohu8.com/highlight/detail?id=1111549440","media":"The Street","summary":"$Bristol Myers Squibb (BMY)$ shares fell Friday after the pharmaceutical titan said the FDA has exte","content":"<p>$Bristol Myers Squibb&nbsp;(<b>BMY</b>)$&nbsp;shares fell Friday after the pharmaceutical titan said the FDA has extended its review of heart drug mavacamten for three months, until April 28.</p>\n<p>The drug treats symptomatic obstructive hypertrophic cardiomyopathy (oHCM).</p>\n<p>The Food and Drug Administration notified Bristol Thursday of the extension “to allow sufficient time to review information pertaining to updates to the proposed Risk Evaluation Mitigation Strategy (REMS),” the company said.</p>\n<p>“A REMS program was included in the initial application for mavacamten. No additional data or studies have been requested.”</p>\n<p>Bristol Myers recently traded at $58.07, down 1.6%. It has slid 14% over the past three months.</p>\n<p>“We are confident in the profile of mavacamten,” said Samit Hirawat, chief medical officer, global drug development at Bristol Myers.</p>\n<p>“This first-in-class cardiac myosin inhibitor demonstrated clinically meaningful improvements in symptoms, functional status, and quality of life in symptomatic oHCM patients in the pivotal EXPLORER-HCM trial.”</p>\n<p>Mavacamten represented the top potential drug of MyoKardia, which Bristol Myers acquired last year for $13.1 billion, MarketWatch reports.</p>\n<p>Morningstar analyst Damien Conover puts fair value for Bristol Myers at $68.</p>\n<p>“Bristol Myers hosted an investor day highlighting a strong pipeline that holds the potential to offset the firm’s major patent losses over the next decade, a key element supporting our wide moat rating,” he wrote in a commentary Tuesday.</p>\n<p>“With most of the updates focused on still risky early-stage pipeline assets, the updates didn’t move our fair value estimate. However, we continue to view the stock as undervalued with the market not fully appreciating the firm’s late-stage pipeline.”</p>","source":"lsy1610613172068","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers Stock Keeps Skidding on FDA Heart Drug Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers Stock Keeps Skidding on FDA Heart Drug Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-20 09:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/bristol-myers-heart-drug-mavacamten-gets-extended-fda-review><strong>The Street</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>$Bristol Myers Squibb (BMY)$ shares fell Friday after the pharmaceutical titan said the FDA has extended its review of heart drug mavacamten for three months, until April 28.\nThe drug treats ...</p>\n\n<a href=\"https://www.thestreet.com/investing/bristol-myers-heart-drug-mavacamten-gets-extended-fda-review\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"source_url":"https://www.thestreet.com/investing/bristol-myers-heart-drug-mavacamten-gets-extended-fda-review","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111549440","content_text":"$Bristol Myers Squibb (BMY)$ shares fell Friday after the pharmaceutical titan said the FDA has extended its review of heart drug mavacamten for three months, until April 28.\nThe drug treats symptomatic obstructive hypertrophic cardiomyopathy (oHCM).\nThe Food and Drug Administration notified Bristol Thursday of the extension “to allow sufficient time to review information pertaining to updates to the proposed Risk Evaluation Mitigation Strategy (REMS),” the company said.\n“A REMS program was included in the initial application for mavacamten. No additional data or studies have been requested.”\nBristol Myers recently traded at $58.07, down 1.6%. It has slid 14% over the past three months.\n“We are confident in the profile of mavacamten,” said Samit Hirawat, chief medical officer, global drug development at Bristol Myers.\n“This first-in-class cardiac myosin inhibitor demonstrated clinically meaningful improvements in symptoms, functional status, and quality of life in symptomatic oHCM patients in the pivotal EXPLORER-HCM trial.”\nMavacamten represented the top potential drug of MyoKardia, which Bristol Myers acquired last year for $13.1 billion, MarketWatch reports.\nMorningstar analyst Damien Conover puts fair value for Bristol Myers at $68.\n“Bristol Myers hosted an investor day highlighting a strong pipeline that holds the potential to offset the firm’s major patent losses over the next decade, a key element supporting our wide moat rating,” he wrote in a commentary Tuesday.\n“With most of the updates focused on still risky early-stage pipeline assets, the updates didn’t move our fair value estimate. However, we continue to view the stock as undervalued with the market not fully appreciating the firm’s late-stage pipeline.”","news_type":1,"symbols_score_info":{"BMY":0.9}},"isVote":1,"tweetType":1,"viewCount":498,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":815053192,"gmtCreate":1630631685916,"gmtModify":1631891867591,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/815053192","repostId":"2164829818","repostType":4,"isVote":1,"tweetType":1,"viewCount":614,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":818119377,"gmtCreate":1630383027899,"gmtModify":1704959475747,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/818119377","repostId":"2163833181","repostType":4,"isVote":1,"tweetType":1,"viewCount":264,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}